

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
For the quarterly period ended September 30, 2024

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
For the transition period from \_\_\_\_\_ to \_\_\_\_\_  
Commission file number 001-34504

**ADDUS HOMECARE CORPORATION**

(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction of  
incorporation or organization)

20-5340172  
(I.R.S. Employer  
Identification No.)

6303 Cowboys Way, Suite 600  
Frisco, TX  
(Address of principal executive offices)

75034  
(Zip Code)

(469) 535-8200

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value	ADUS	The Nasdaq Stock Market, LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer  Accelerated Filer   
Non-Accelerated Filer  Smaller Reporting Company   
Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of October 29, 2024, Addus HomeCare Corporation had 18,133,115 shares of Common Stock outstanding.

**ADDUS HOMECARE CORPORATION**

**FORM 10-Q**

**INDEX**

<a href="#">PART I. FINANCIAL INFORMATION</a>	3
<a href="#">Item 1. Financial Statements (Unaudited)</a>	3
<a href="#">Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023</a>	3
<a href="#">Condensed Consolidated Statements of Income For the Three and Nine Months Ended September 30, 2024 and 2023</a>	4
<a href="#">Condensed Consolidated Statement of Stockholders' Equity For the Three and Nine Months Ended September 30, 2024 and 2023</a>	5
<a href="#">Condensed Consolidated Statements of Cash Flows For the Nine Months Ended September 30, 2024 and 2023</a>	7
<a href="#">Notes to Condensed Consolidated Financial Statements</a>	8
<a href="#">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</a>	21
<a href="#">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a>	37
<a href="#">Item 4. Controls and Procedures</a>	37
<a href="#">PART II. OTHER INFORMATION</a>	38
<a href="#">Item 1. Legal Proceedings</a>	38
<a href="#">Item 1A. Risk Factors</a>	38
<a href="#">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a>	38
<a href="#">Item 3. Defaults Upon Senior Securities</a>	38
<a href="#">Item 4. Mine Safety Disclosures</a>	39
<a href="#">Item 5. Other Information</a>	39
<a href="#">Item 6. Exhibits</a>	40

**PART I – FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**ADDUS HOMECARE CORPORATION  
AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED BALANCE SHEETS**  
**As of September 30, 2024 and December 31, 2023**  
**(Amounts and Shares in Thousands, Except Per Share Data)**  
**(Unaudited)**

	September 30, 2024	December 31, 2023
<b>Assets</b>		
Current assets		
Cash	\$ 222,852	\$ 64,791
Accounts receivable, net of allowances	96,600	115,499
Prepaid expenses and other current assets	13,362	19,714
Total current assets	332,814	200,004
Property and equipment, net of accumulated depreciation and amortization	23,716	24,011
Other assets		
Goodwill	663,614	662,995
Intangibles, net of accumulated amortization	86,606	91,983
Operating lease assets, net	44,535	45,433
Other long-term assets	1,616	—
Total other assets	796,371	800,411
Total assets	\$ 1,152,901	\$ 1,024,426
<b>Liabilities and stockholders' equity</b>		
Current liabilities		
Accounts payable	\$ 27,726	\$ 26,183
Accrued payroll	57,982	56,551
Accrued expenses	34,257	33,236
Operating lease liabilities, current portion	11,155	11,339
Government stimulus advances	13,655	5,765
Accrued workers' compensation insurance	13,043	12,043
Total current liabilities	157,818	145,117
Long-term liabilities		
Long-term debt, net of debt issuance costs	—	124,132
Long-term operating lease liabilities	38,608	39,711
Other long-term liabilities	8,841	8,772
Total long-term liabilities	47,449	172,615
Total liabilities	\$ 205,267	\$ 317,732
Stockholders' equity		
Common stock—\$.001 par value; 40,000 authorized and 18,133 and 16,227 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively	\$ 18	\$ 16
Additional paid-in capital	590,712	403,846
Retained earnings	356,904	302,832
Total stockholders' equity	947,634	706,694
Total liabilities and stockholders' equity	\$ 1,152,901	\$ 1,024,426

See accompanying Notes to Condensed Consolidated Financial Statements (Unaudited)

**ADDUS HOMECARE CORPORATION  
AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF INCOME**  
**For the Three and Nine Months Ended September 30, 2024 and 2023**  
**(Amounts and Shares in Thousands, Except Per Share Data)**  
**(Unaudited)**

	<b>For the Three Months Ended September 30,</b>		<b>For the Nine Months Ended September 30,</b>	
	<b>2024</b>	<b>2023</b>	<b>2024</b>	<b>2023</b>
Net service revenues	\$ 289,787	\$ 270,721	\$ 857,455	\$ 782,300
Cost of service revenues	197,583	183,991	583,916	534,837
Gross profit	92,204	86,730	273,539	247,463
General and administrative expenses	62,805	60,271	187,444	174,028
Depreciation and amortization	3,446	3,620	10,316	10,449
Total operating expenses	66,251	63,891	197,760	184,477
Operating income	25,953	22,839	75,779	62,986
Interest income	(1,908)	(580)	(2,805)	(977)
Interest expense	573	3,199	5,445	7,991
Total interest (income) expense, net	(1,335)	2,619	2,640	7,014
Income before income taxes	27,288	20,220	73,139	55,972
Income tax expense	7,125	4,809	19,067	13,034
Net income	\$ 20,163	\$ 15,411	\$ 54,072	\$ 42,938
Net income per common share				
Basic income per share	\$ 1.13	\$ 0.96	\$ 3.24	\$ 2.69
Diluted income per share	\$ 1.10	\$ 0.95	\$ 3.17	\$ 2.63
Weighted average number of common shares and potential common shares outstanding:				
Basic	17,868	16,012	16,707	15,988
Diluted	18,255	16,286	17,065	16,307

See accompanying Notes to Condensed Consolidated Financial Statements (Unaudited)

**ADDUS HOMECARE CORPORATION  
AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**  
**For the Three and Nine Months Ended September 30, 2024**  
**(Amounts and Shares in Thousands)**  
**(Unaudited)**

	For the Three Months Ended September 30, 2024				
	Common Stock		Additional Paid-in Capital	Retained Earnings	Total Stockholders' Equity
	Shares	Amount			
Balance at July 1, 2024	18,100	\$ 18	\$ 584,896	\$ 336,741	\$ 921,655
Issuance of shares of common stock under restricted stock award agreements	—	—	—	—	—
Forfeiture of shares of common stock under restricted stock award agreements	(2)	—	—	—	—
Stock-based compensation	—	—	2,833	—	2,833
Shares issued for exercise of stock options	35	—	2,983	—	2,983
Net income	—	—	—	20,163	20,163
Balance at September 30, 2024	<u>18,133</u>	<u>\$ 18</u>	<u>\$ 590,712</u>	<u>\$ 356,904</u>	<u>\$ 947,634</u>
	For the Nine Months Ended September 30, 2024				
	Common Stock		Additional Paid-in Capital	Retained Earnings	Total Stockholders' Equity
	Shares	Amount			
Balance at January 1, 2024	16,227	\$ 16	\$ 403,846	\$ 302,832	\$ 706,694
Issuance of shares of common stock under restricted stock award agreements	151	—	—	—	—
Forfeiture of shares of common stock under restricted stock award agreements	(5)	—	—	—	—
Stock-based compensation	—	—	8,307	—	8,307
Shares issued for exercise of stock options	35	—	2,983	—	2,983
Shares issued in public offering, net of offering costs	1,725	2	175,576	—	175,578
Net income	—	—	—	54,072	54,072
Balance at September 30, 2024	<u>18,133</u>	<u>\$ 18</u>	<u>\$ 590,712</u>	<u>\$ 356,904</u>	<u>\$ 947,634</u>

See accompanying Notes to Condensed Consolidated Financial Statements (Unaudited)

**ADDUS HOMECARE CORPORATION  
AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY  
For the Three and Nine Months Ended September 30, 2023  
(Amounts and Shares in Thousands)  
(Unaudited)**

	For the Three Months Ended September 30, 2023				
	Common Stock		Additional Paid-in Capital	Retained Earnings	Total Stockholders' Equity
	Shares	Amount			
Balance at July 1, 2023	16,214	\$ 16	\$ 398,492	\$ 267,843	\$ 666,351
Issuance of shares of common stock under restricted stock award agreements	—	—	—	—	—
Forfeiture of shares of common stock under restricted stock award agreements	—	—	—	—	—
Stock-based compensation	—	—	2,572	—	2,572
Shares issued for exercise of stock options	—	—	—	—	—
Net income	—	—	—	15,411	15,411
Balance at September 30, 2023	<u>16,214</u>	<u>\$ 16</u>	<u>\$ 401,064</u>	<u>\$ 283,254</u>	<u>\$ 684,334</u>
	For the Nine Months Ended September 30, 2023				
	Common Stock		Additional Paid-in Capital	Retained Earnings	Total Stockholders' Equity
	Shares	Amount			
Balance at January 1, 2023	16,128	\$ 16	\$ 393,208	\$ 240,316	\$ 633,540
Issuance of shares of common stock under restricted stock award agreements	86	—	—	—	—
Forfeiture of shares of common stock under restricted stock award agreements	—	—	—	—	—
Stock-based compensation	—	—	7,831	—	7,831
Shares issued for exercise of stock options	—	—	25	—	25
Net income	—	—	—	42,938	42,938
Balance at September 30, 2023	<u>16,214</u>	<u>\$ 16</u>	<u>\$ 401,064</u>	<u>\$ 283,254</u>	<u>\$ 684,334</u>

See accompanying Notes to Condensed Consolidated Financial Statements (Unaudited)

**ADDUS HOMECARE CORPORATION  
AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**For the Nine Months Ended September 30, 2024 and 2023**  
**(Amounts in Thousands)**  
**(Unaudited)**

	For the Nine Months Ended September 30,	
	2024	2023
Cash flows from operating activities:		
Net income	\$ 54,072	\$ 42,938
Adjustments to reconcile net income to net cash provided by operating activities, net of acquisitions:		
Depreciation and amortization	10,316	10,449
Deferred income taxes	188	246
Stock-based compensation	8,307	7,831
Amortization of debt issuance costs under the credit facility	644	645
Provision for credit losses	812	508
Gain on disposal of assets	(13)	—
Loss on termination of operating leases	9	—
Impairment of operating lease assets	—	8
Changes in operating assets and liabilities, net of acquisitions:		
Accounts receivable	17,868	9,929
Prepaid expenses and other current assets	6,187	6,277
Government stimulus advances	7,890	(5,528)
Accounts payable	1,003	(2,118)
Accrued payroll	1,431	4,464
Accrued expenses and other long-term liabilities	(2,698)	6,549
Net cash provided by operating activities	<u>106,016</u>	<u>82,198</u>
Cash flows from investing activities:		
Acquisitions of businesses, net of cash acquired	(400)	(109,800)
Purchases of property and equipment	(4,353)	(4,134)
Proceeds received from disposal of assets	29	—
Proceeds received from divestiture of business	4,600	—
Net cash used in investing activities	<u>(124)</u>	<u>(113,934)</u>
Cash flows from financing activities:		
Payments on revolver loan — credit facility	(126,353)	(78,500)
Proceeds from borrowings on revolver — credit facility	—	110,000
Proceeds from public offering	175,578	—
Payment for debt issuance costs	(39)	—
Cash received from exercise of stock options	2,983	25
Net cash provided by financing activities	<u>52,169</u>	<u>31,525</u>
Net change in cash	158,061	(211)
Cash, at beginning of period	64,791	79,961
Cash, at end of period	<u>\$ 222,852</u>	<u>\$ 79,750</u>
Supplemental disclosures of cash flow information:		
Cash paid for interest	\$ 4,801	\$ 7,364
Cash paid for income taxes	19,436	10,565

See accompanying Notes to Condensed Consolidated Financial Statements (Unaudited)

**ADDUS HOMECARE CORPORATION  
AND SUBSIDIARIES**

**Notes to Condensed Consolidated Financial Statements  
(Unaudited)**

**1. Nature of Operations, Consolidation and Presentation of Financial Statements**

Addus HomeCare Corporation (“Holdings”) and its subsidiaries (together with Holdings, the “Company”, “we”, “us” or “our”) operate as a multi-state provider of three distinct but related business segments providing in-home services. In its personal care services segment, the Company provides non-medical assistance with activities of daily living, primarily to persons who are at increased risk of hospitalization or institutionalization, such as the elderly, chronically ill or disabled. In its hospice segment, the Company provides physical, emotional and spiritual care for people who are terminally ill as well as related services for their families. In its home health segment, the Company provides services that are primarily medical in nature to individuals who may require assistance during an illness or after hospitalization and include skilled nursing and physical, occupational and speech therapy. The Company’s payors include federal, state and local governmental agencies, managed care organizations, commercial insurers and private individuals.

***Basis of Presentation***

The accompanying Unaudited Condensed Consolidated Financial Statements and related notes have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for Quarterly Reports on Form 10-Q. The accompanying balance sheet as of December 31, 2023 has been derived from the Company’s audited financial statements for the year ended December 31, 2023 previously filed with the SEC. Accordingly, these financial statements do not include all of the information and note disclosures required by accounting principles generally accepted in the United States of America (“GAAP”) for annual financial statements and should be read in conjunction with our consolidated financial statements and notes thereto for the year ended December 31, 2023 included in our Annual Report on Form 10-K, which includes information and disclosures not included herein.

In the opinion of management, these financial statements reflect all adjustments of a normal, recurring nature necessary for the fair statement of our financial position, results of operations and cash flows for the interim periods presented in conformity with GAAP. Our results for any interim period are not necessarily indicative of results for a full year or any other interim period.

***Principles of Consolidation***

These Unaudited Condensed Consolidated Financial Statements include the accounts of Addus HomeCare Corporation, and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

**2. Summary of Significant Accounting Policies**

***Estimates***

The financial statements are prepared by management in conformity with GAAP and include estimated amounts and certain disclosures based on assumptions about future events. The Company’s critical accounting estimates include the following areas: revenue recognition, goodwill and intangibles in business combinations and when required, the quantitative assessment of goodwill. Actual results could differ from those estimates.



## [Table of Contents](#)

### **Computation of Weighted Average Shares**

The following table sets forth the computation of basic and diluted common shares:

	For the Three Months Ended September 30, (Amounts in thousands)		For the Nine Months Ended September 30, (Amounts in thousands)	
	2024	2023	2024	2023
Weighted average number of shares outstanding for basic per share calculation	17,868	16,012	16,707	15,988
Effect of dilutive potential shares:				
Stock options	278	227	254	239
Restricted stock awards	109	47	104	80
Adjusted weighted average shares outstanding for diluted per share calculation	18,255	16,286	17,065	16,307
Anti-dilutive shares:				
Stock options	—	111	—	61
Restricted stock awards	—	1	—	1

### **Recently Adopted Accounting Pronouncements**

In October 2021, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (Topic 805). This ASU requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities (deferred revenue) from acquired contracts using the revenue recognition guidance in Topic 606. At the acquisition date, the acquirer applies the revenue model as if it had originated the acquired contracts. The ASU was adopted prospectively on January 1, 2023. The additional disclosures required did not have a material impact on our consolidated financial statements.

### **Recently Issued Accounting Pronouncements**

In November 2023, the FASB issued ASU 2023-07, *Improvements to Reportable Segment Disclosures*, which expands reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments in the ASU require, among other things, disclosure of significant segment expenses that are regularly provided to an entity’s chief operating decision maker (“CODM”) and a description of other segment items (the difference between segment revenue less the segment expenses disclosed under the significant expense principle and each reported measure of segment profit or loss) by reportable segment, as well as disclosure of the title and position of the CODM, and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. Annual disclosures are required for fiscal years beginning after December 15, 2023 and interim disclosures are required for periods within fiscal years beginning after December 15, 2024. Retrospective application is required, and early adoption is permitted. These requirements will result in expanded disclosures.

In December 2023, the FASB issued ASU 2023-09, *Improvement to Income Tax Disclosures*, which requires disclosure of disaggregated income taxes paid, prescribes standard categories for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, may be applied prospectively or retrospectively, and allows for early adoption. These requirements are not expected to have an impact on the Company’s financial statements and will expand income tax disclosures.

### **3. Public Offering**

On June 28, 2024, the Company completed a public offering of an aggregate 1,725,000 shares of common stock, par value \$0.001 per share, including 225,000 shares of common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a public offering price of \$108.00 per share (the “Public Offering”). The Company received net proceeds of approximately \$175.6 million, after deducting underwriting discounts and estimated offering expenses of approximately \$10.7 million. The Company used approximately \$81.4 million from the net proceeds of the Public Offering for the repayment of indebtedness outstanding under its credit facility and may use any remaining net proceeds of the Public Offering for general corporate purposes, including the Company’s previously announced planned acquisition of the personal care assets of Gentiva and any future acquisitions or investments. The Public Offering resulted in an increase to additional paid in capital of approximately \$175.6 million on the Company’s Unaudited Condensed Consolidated Balance Sheets at June 30, 2024.

#### 4. Acquisition and Divestiture

##### *Acquisition*

On June 8, 2024, the Company entered into a definitive stock and asset purchase agreement (the “Gentiva Purchase Agreement”) to acquire the personal care operations of Curo Health Services, LLC, a Delaware limited liability company which does business as Gentiva (“Gentiva”), consisting of equity interests and certain assets and liabilities, for a purchase price of approximately \$350.0 million, payable in full in cash at the closing, subject to typical adjustments for working capital and other customary items (collectively, the “Gentiva Acquisition”). The acquired business operates in Arizona, Arkansas, California, Missouri, North Carolina, Tennessee and Texas, and serves approximately 16,000 patients. The Company expects to close this acquisition following completion of regulatory approvals and subject to customary closing conditions and fund it through the Company’s existing revolving credit facility and a portion of the net proceeds from the Public Offering.

##### *Divestiture*

On May 21, 2024, the Company entered into a definitive asset purchase agreement to sell all of the Company’s New York operations for a purchase price of up to \$23.0 million in cash, subject to certain adjustments, including adjustments for future operating requirements (the “New York Asset Sale”). The Company entered into a consulting agreement with the purchaser on May 21, 2024, as the transfer of clients and caregivers and payment for assets pursuant to the New York Asset Sale is occurring over time as regulatory approvals are received, coordination of the transfer of clients and caregivers occurs, and the change of control takes place. In connection with this transaction, the Company will cease operations in New York. During the three and nine months ended September 30, 2024, the Company recorded \$1.0 million and \$1.7 million in consulting fees, respectively, and received a \$4.6 million initial payment on the acquisition.

The New York Asset Sale did not qualify as a discontinued operation because it did not represent a strategic shift that has or will have a major effect on the Company’s operation or financial results.

As of May 21, 2024, the Company’s New York personal care operations met the criteria to be classified as held for sale. The carrying value does not exceed the fair market value and will result in a gain on divestiture once the transaction closes. See Note 14 to the Notes to Unaudited Condensed Consolidated Financial Statements, *Subsequent Events*, for additional details regarding the treatment of the New York Asset Sale.

The carrying amounts of the assets and liabilities associated with our New York personal care operations included in our Unaudited Condensed Consolidated Balance Sheets as of September 30, 2024 were as follows (amounts in thousands):

	<b>September 30, 2024</b>
<b>Assets</b>	
Current assets	
Accounts receivable, net of allowances	\$ 8,311
Prepaid expenses and other current assets	25
<b>Total current assets</b>	<b>8,336</b>
Property and equipment, net of accumulated depreciation and amortization	29
Other assets	
Goodwill	3,801
Intangibles, net of accumulated amortization	4,203
Operating lease assets, net	3,510
<b>Total other assets</b>	<b>11,514</b>
<b>Total assets</b>	<b>\$ 19,879</b>
<b>Liabilities</b>	
Current liabilities	
Accounts payable	\$ 6,020
Accrued payroll	3,338
Accrued expenses	680
Operating lease liabilities, current portion	751
<b>Total current liabilities</b>	<b>10,789</b>
Long-term liabilities	
Other long-term liabilities	2,661
<b>Total liabilities</b>	<b>\$ 13,450</b>

[Table of Contents](#)

**5. Leases**

Amounts reported on the Company's Unaudited Condensed Consolidated Balance Sheets for operating leases were as follows:

	September 30, 2024	December 31, 2023
	(Amounts in Thousands)	
Operating lease assets, net	\$ 44,535	\$ 45,433
Short-term operating lease liabilities (in accrued expenses)	11,155	11,339
Long-term operating lease liabilities	38,608	39,711
Total operating lease liabilities	<u>\$ 49,763</u>	<u>\$ 51,050</u>

**Lease Costs**

Components of lease costs were reported in general and administrative expenses in the Company's Unaudited Condensed Consolidated Statements of Income as follows:

	For the Three Months Ended September 30, (Amounts in Thousands)		For the Nine Months Ended September 30, (Amounts in Thousands)	
	2024	2023	2024	2023
Operating lease costs	\$ 3,393	\$ 3,344	\$ 10,062	\$ 9,678
Short-term lease costs	167	249	547	949
Total lease costs	3,560	3,593	10,609	10,627
Less: sublease income	(596)	(704)	(1,685)	(2,104)
Total lease costs, net	<u>\$ 2,964</u>	<u>\$ 2,889</u>	<u>\$ 8,924</u>	<u>\$ 8,523</u>

**Lease Term and Discount Rate**

Weighted average remaining lease terms and discount rates were as follows:

	September 30, 2024	December 31, 2023
Operating leases:		
Weighted average remaining lease term (years)	5.81	6.26
Weighted average discount rate	5.99%	5.47%

**Maturity of Lease Liabilities**

Remaining operating lease payments as of September 30, 2024 were as follows:

	Operating Leases (Amounts in Thousands)	
Due in the 12-month period ended September 30,		
2025	\$	13,786
2026		11,097
2027		8,506
2028		6,322
2029		5,722
Thereafter		14,019
Total future minimum rental commitments		<u>59,452</u>
Less: Imputed interest		<u>(9,689)</u>
Total lease liabilities	<u>\$</u>	<u>49,763</u>

### Supplemental Cash Flows Information

	For the Nine Months Ended September 30, (Amounts in Thousands)	
	2024	2023
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows from operating leases	\$ 10,925	\$ 10,702
Right-of-use assets obtained in exchange for lease obligations:		
Operating leases	\$ 7,683	\$ 15,903

### 6. Goodwill and Intangible Assets

A summary of the goodwill and related adjustments is provided below:

	Hospice	Personal Care	Home Health	Total
	(Amounts in Thousands)			
Goodwill as of December 31, 2023	\$ 432,799	\$ 153,276	\$ 76,920	\$ 662,995
Additions for acquisitions	—	400	—	400
Adjustments to previously recorded goodwill	41	—	178	219
Goodwill as of September 30, 2024	\$ 432,840	\$ 153,676	\$ 77,098	\$ 663,614

On March 9, 2024, the Company completed its acquisition of the operations of Upstate Home Care Solutions (“Upstate”) for \$0.4 million. With the purchase of Upstate, the Company expanded its personal care services segment in South Carolina. In connection with the Upstate acquisition, the Company recognized goodwill in its personal care segment of \$0.4 million during the nine months ended September 30, 2024.

The Company’s identifiable intangible assets consist of customer and referral relationships, trade names and trademarks, non-competition agreements and state licenses. Amortization is computed using straight-line and accelerated methods based upon the estimated useful lives of the respective assets, which range from one to twenty years. Customer and referral relationships are amortized systematically over the periods of expected economic benefit, which range from five to ten years.

The carrying amount and accumulated amortization of each identifiable intangible asset category consisted of the following:

	Estimated Useful Life	September 30, 2024 (Amounts in Thousands)			December 31, 2023 (Amounts in Thousands)		
		Gross carrying value	Accumulated amortization	Net carrying value	Gross carrying value	Accumulated amortization	Net carrying value
Customer and referral relationships	5-10 years	\$ 44,672	\$ (40,588)	\$ 4,084	\$ 44,672	\$ (39,566)	\$ 5,106
Trade names and trademarks	1-20 years	59,566	(26,112)	33,454	59,566	(23,857)	35,709
Non-competition agreement	3-5 years	6,785	(6,213)	572	6,785	(5,601)	1,184
State Licenses	6-10 years	12,671	(10,503)	2,168	12,671	(9,015)	3,656
State Licenses	Indefinite	46,328	—	46,328	46,328	—	46,328
Total intangible assets		\$ 170,022	\$ (83,416)	\$ 86,606	\$ 170,022	\$ (78,039)	\$ 91,983

Amortization expense related to the intangible assets was \$1.8 million and \$5.4 million for the three and nine months ended September 30, 2024, respectively, and \$1.8 million and \$5.3 million for the three and nine months ended September 30, 2023, respectively. The weighted average remaining useful lives of identifiable intangible assets as of September 30, 2024 was 10.0 years.

## 7. Details of Certain Balance Sheet Accounts

Prepaid expenses and other current assets consisted of the following:

	<u>September 30, 2024</u>	<u>December 31, 2023</u>
	(Amounts in Thousands)	
Prepaid payroll	\$ 2,585	\$ 8,735
Prepaid workers' compensation and liability insurance	3,112	3,696
Prepaid licensing fees	4,361	4,481
Workers' compensation insurance receivable	837	577
Other	2,467	2,225
Total prepaid expenses and other current assets	<u>\$ 13,362</u>	<u>\$ 19,714</u>

Accrued expenses consisted of the following:

	<u>September 30, 2024</u>	<u>December 31, 2023</u>
	(Amounts in Thousands)	
Accrued health benefits	\$ 6,032	\$ 7,400
Payor advances <sup>(1)</sup>	—	1,218
Accrued professional fees	7,038	7,304
Accrued payroll and other taxes	7,213	8,572
Other <sup>(2)</sup>	13,974	8,742
Total accrued expenses	<u>\$ 34,257</u>	<u>\$ 33,236</u>

(1) Represents the deferred portion of payments received from payors for COVID-19 reimbursements which was recognized as we incurred specific COVID-19 related expenses (including expenses related to securing and maintaining adequate personnel).

(2) Includes a \$4.6 million initial payment received for the New York Asset Sale as of September 30, 2024.

## 8. Government Actions to Mitigate COVID-19's Impact

While the acute phase of the COVID-19 pandemic has faded, we will continue to closely monitor the impact of COVID-19 on all aspects of our business, including the impacts to our employees, patients and suppliers.

In recognition of the significant threat to the liquidity of financial markets posed by the COVID-19 pandemic, the Federal Reserve and Congress took dramatic actions to provide liquidity to businesses and the banking system in the United States, including relief for healthcare providers in the Coronavirus Aid, Relief, and Economic Stability Act ("CARES Act"), which was expanded by the Paycheck Protection Program and Health Care Enhancement Act, and the Consolidated Appropriations Act, 2021 ("CAA"), as well as the American Rescue Plan Act of 2021 ("ARPA").

### *ARPA Spending Plans*

The ARPA provides for \$350 billion in relief funding for eligible state, local, territorial, and Tribal governments to mitigate the fiscal effects of the COVID-19 public health emergency. Additionally, the law provided for a 10 percentage point increase in federal matching funds for Medicaid home and community-based services ("HCBS") from April 1, 2021, through March 31, 2022, provided the state satisfied certain conditions. States are permitted to use the state funds equivalent to the additional federal funds through March 31, 2025. States must use the monies attributable to this matching fund increase to supplement, not supplant, their level of state spending for the implementation of activities enhanced under the Medicaid HCBS in effect as of April 1, 2021.

HCBS spending plans for the additional matching funds vary by state, but common initiatives in which the Company is participating include those aimed at strengthening the provider workforce (e.g., efforts to recruit, retain, and train direct service providers). The Company is required to properly and fully document the use of such funds in reports to the state in which the funds originated. Funds may be subject to recoupment if not expended or if they are expended on non-approved uses.

## [Table of Contents](#)

During the three and nine months ended September 30, 2024, the Company received additional state funding provided by the ARPA in an aggregate amount of \$3.2 million and \$15.4 million, respectively. Of the total state funding received by the Company pursuant to the ARPA through September 30, 2024, the Company utilized \$2.6 million and \$7.5 million during the three and nine months ended September 30, 2024, respectively, primarily for caregivers and adding support to recruiting and retention efforts, included as a reduction of cost of service revenues in the Company's Unaudited Condensed Consolidated Statements of Income. As of September 30, 2024, the deferred portion of ARPA funding of \$13.7 million is included within Government stimulus advances on the Company's Unaudited Condensed Consolidated Balance Sheets.

### *Medicare Sequester*

The CARES Act and related legislation also include other provisions offering financial relief, including, for example, temporarily suspending the Medicare sequester, which would have otherwise reduced payments to Medicare providers by 2% as required by the Budget Control Act of 2011. The sequestration adjustment resumed with a 1% reduction beginning April 1, 2022, and a 2% reduction beginning July 1, 2022. These sequestration cuts have been extended through April 2022.

The ARPA increased the federal budget deficit in a manner that triggers an additional statutorily mandated sequestration under the PAYGO Act. As a result, an additional Medicare payment reduction of up to 4% was required to take effect in January 2022. However, Congress has delayed implementation of this payment reduction until 2025.

## **9. Long-Term Debt**

Long-term debt consisted of the following:

	<u>September 30, 2024</u>	<u>December 31, 2023</u>
	(Amounts in Thousands)	
Revolving loan under the credit facility	\$ —	\$ 126,353
Less unamortized issuance costs <sup>(1)</sup>	—	(2,221)
Long-term debt	<u>\$ —</u>	<u>\$ 124,132</u>

(1) As of September 30, 2024, unamortized issuance costs of \$1.6 million are recorded in Other long-term assets on the Company's Unaudited Condensed Consolidated Balance Sheets.

### ***Amended and Restated Senior Secured Credit Facility***

On October 31, 2018, the Company entered into the Amended and Restated Credit Agreement, with certain lenders and Capital One, National Association, as a lender and as agent for all lenders, as amended by the First Amendment to Amended and Restated Credit Agreement, dated as of September 12, 2019, as further amended by the Second Amendment to Amended and Restated Credit Agreement, dated as of July 30, 2021, and as further amended by the Third Amendment to Amended and Restated Credit Agreement, dated as of April 26, 2023 (as described below, the "Third Amendment") (as amended, the "Credit Agreement", as used throughout this Quarterly Report on Form 10-Q, "credit facility" shall mean the credit facility evidenced by the Credit Agreement). As discussed further in Note 14, the credit facility consists of a \$650.0 million revolving credit facility and a \$150.0 million incremental loan facility, which incremental loan facility may be for term loans or an increase to the revolving loan commitments. The maturity of this credit facility is July 30, 2028.

On April 26, 2023, the Company entered into the Third Amendment to replace LIBOR with the Secured Overnight Financing Rate ("SOFR") as the benchmark reference rate for loans under its credit facility. The Third Amendment did not amend any other terms of the Credit Agreement. The transition to SOFR did not and is not expected to have a material impact on the Company's results of operations or liquidity.

Interest on the credit facility may be payable at (x) the sum of (i) an applicable margin ranging from 0.75% to 1.50% based on the applicable senior net leverage ratio plus (ii) a base rate equal to the greatest of (a) the rate of interest last quoted by The Wall Street Journal as the "prime rate," (b) the sum of the federal funds rate plus a margin of 0.50% and (c) the sum of Term SOFR (as published by the CME Group Benchmark Administrative Limited) for an interest period of one month for such applicable day plus 0.10% (not to be less than 0.00%), plus a margin of 1.00% or (y) the sum of (i) an applicable margin ranging from 1.75% to 2.50% based on the applicable senior net leverage ratio plus (ii) the rate per annum equal to the sum of Term SOFR (as published by the CME Group Benchmark Administrative Limited) for the applicable interest period plus 0.10% (not to be less than zero). Swing loans may not be SOFR loans.

## [Table of Contents](#)

Addus HealthCare, Inc. (“Addus HealthCare”) is the borrower, and its parent, Holdings, and substantially all of Holdings’ subsidiaries are guarantors under this credit facility, and it is collateralized by a first priority security interest in all of the Company’s and the other credit parties’ current and future tangible and intangible assets, including the shares of stock of the borrower and subsidiaries. The Credit Agreement contains affirmative and negative covenants customary for credit facilities of this type, including limitations on the Company with respect to liens, indebtedness, guaranties, investments, distributions, mergers and acquisitions and dispositions of assets. The availability of additional draws under this credit facility is conditioned, among other things, upon (after giving effect to such draws) the Total Net Leverage Ratio (as defined in the Credit Agreement) not exceeding 3.75:1.00. In certain circumstances, in connection with a Material Acquisition (as defined in the Credit Agreement), the Company can elect to increase its Total Net Leverage Ratio compliance covenant to 4.25:1.00 for the then current fiscal quarter and the three succeeding fiscal quarters.

The Company pays a fee ranging from 0.20% to 0.35% based on the applicable senior net leverage ratio times the unused portion of the revolving loan portion of the credit facility.

The Credit Agreement contains customary affirmative covenants regarding, among other things, the maintenance of records, compliance with laws, maintenance of permits, maintenance of insurance and property and payment of taxes. The Credit Agreement also contains certain customary financial covenants and negative covenants that, among other things, include a requirement to maintain a minimum Interest Coverage Ratio (as defined in the Credit Agreement), a requirement to stay below a maximum Total Net Leverage Ratio (as defined in the Credit Agreement) and a requirement to stay below a maximum permitted amount of capital expenditures. The Credit Agreement also contains restrictions on guaranties, indebtedness, liens, investments and loans, subject to customary carve outs, a restriction on dividends (provided that Addus HealthCare may make distributions to the Company in an amount that does not exceed \$7.5 million in any year absent of an event of default, plus limited exceptions for tax and administrative distributions), a restriction on the ability to consummate acquisitions (without the consent of the lenders) under its credit facility subject to compliance with the Total Net Leverage Ratio (as defined in the Credit Agreement) thresholds, restrictions on mergers, dispositions of assets, and affiliate transactions, and restrictions on fundamental changes and lines of business.

During the nine months ended September 30, 2024, the Company did not draw on its credit facility and repaid all amounts owed under the revolving credit facility. During the nine months ended September 30, 2023, the Company (i) drew \$110.0 million under its credit facility to fund, in part, the Tennessee Quality Care acquisition and (ii) repaid \$78.5 million under the revolving credit facility.

As of September 30, 2024, the Company had no revolving loans outstanding on its credit facility. After giving effect to the amount drawn on its credit facility, approximately \$8.0 million of outstanding letters of credit and borrowing limits based on an advance multiple of adjusted EBITDA (as defined in the Credit Agreement), the Company had \$511.5 million of capacity and \$503.5 million available for borrowing under its credit facility. As of December 31, 2023, the Company had a total of \$126.4 million of revolving loans, with an interest rate of 7.21%, outstanding on its credit facility.

As of September 30, 2024, the Company was in compliance with all financial covenants under the Credit Agreement.

## **10. Income Taxes**

The effective income tax rates were 26.1% and 23.8% for the three months ended September 30, 2024 and 2023, respectively. The effective income tax rates were 26.1% and 23.3% for the nine months ended September 30, 2024 and 2023, respectively. The difference between our federal statutory rate of 21% and our effective income tax rates is principally due to the inclusion of state taxes and non-deductible compensation, partially offset by the use of federal employment tax credits.

## **11. Commitments and Contingencies**

### ***Legal Proceedings***

From time to time, the Company is subject to legal and/or administrative proceedings incidental to its business.

It is the opinion of management that the outcome of pending legal and/or administrative proceedings will not have a material effect on the Company’s Unaudited Condensed Consolidated Balance Sheets and Unaudited Condensed Consolidated Statements of Income.

## 12. Segment Information

Operating segments are defined as components of a company that engage in business activities from which it may earn revenues and incur expenses, and for which separate financial information is available and is regularly reviewed by the Company's CODM, to assess the performance of the individual segments and make decisions about resources to be allocated to the segments. The Company operates as a multi-state provider of three distinct but related business segments providing in-home services.

In its personal care segment, the Company provides non-medical assistance with activities of daily living, primarily to persons who are at increased risk of hospitalization or institutionalization, such as the elderly, chronically ill or disabled. In its hospice segment, the Company provides physical, emotional and spiritual care for people who are terminally ill as well as related services for their families. In its home health segment, the Company provides services that are primarily medical in nature to individuals who may require assistance during an illness or after hospitalization and include skilled nursing and physical, occupational and speech therapy.

The tables below set forth information about the Company's reportable segments, along with the items necessary to reconcile the segment information to the totals reported in the accompanying Unaudited Condensed Consolidated Financial Statements. Segment assets are not reviewed by the Company's CODM function and therefore are not disclosed below.

Segment operating income consists of revenue generated by a segment, less the direct costs of service revenues and general and administrative expenses that are incurred directly by the segment. Unallocated general and administrative costs are those costs for functions performed in a centralized manner and therefore not attributable to a particular segment. These costs include accounting, finance, human resources, legal, information technology, corporate office support and facility costs and overall corporate management.

	For the Three Months Ended September 30, 2024			
	(Amounts in Thousands)			
	Personal Care	Hospice	Home Health	Total
Net service revenues	\$ 215,433	\$ 57,309	\$ 17,045	\$ 289,787
Cost of services revenues	156,273	30,469	10,841	197,583
Gross profit	59,160	26,840	6,204	92,204
General and administrative expenses	17,489	14,070	4,338	35,897
Segment operating income	\$ 41,671	\$ 12,770	\$ 1,866	\$ 56,307

	For the Three Months Ended September 30, 2023			
	(Amounts in Thousands)			
	Personal Care	Hospice	Home Health	Total
Net service revenues	\$ 201,882	\$ 53,121	\$ 15,718	\$ 270,721
Cost of services revenues	145,808	28,155	10,028	183,991
Gross profit	56,074	24,966	5,690	86,730
General and administrative expenses	16,096	13,246	4,131	33,473
Segment operating income	\$ 39,978	\$ 11,720	\$ 1,559	\$ 53,257

	For the Three Months Ended September 30,	
	2024	2023
	(Amounts in Thousands)	
Segment reconciliation:		
Total segment operating income	\$ 56,307	\$ 53,257
Items not allocated at segment level:		
Other general and administrative expenses	26,908	26,798
Depreciation and amortization	3,446	3,620
Interest income	(1,908)	(580)
Interest expense	573	3,199
Income before income taxes	\$ 27,288	\$ 20,220



## Table of Contents

For the Nine Months Ended September 30, 2024				
(Amounts in Thousands)				
	Personal Care	Hospice	Home Health	Total
Net service revenues	\$ 636,253	\$ 169,202	\$ 52,000	\$ 857,455
Cost of services revenues	461,564	89,166	33,186	583,916
Gross profit	174,689	80,036	18,814	273,539
General and administrative expenses	49,907	40,975	13,447	104,329
Segment operating income	<u>\$ 124,782</u>	<u>\$ 39,061</u>	<u>\$ 5,367</u>	<u>\$ 169,210</u>

  

For the Nine Months Ended September 30, 2023				
(Amounts in Thousands)				
	Personal Care	Hospice	Home Health	Total
Net service revenues	\$ 590,227	\$ 152,414	\$ 39,659	\$ 782,300
Cost of services revenues	428,163	82,028	24,646	534,837
Gross profit	162,064	70,386	15,013	247,463
General and administrative expenses	48,299	39,028	9,653	96,980
Segment operating income	<u>\$ 113,765</u>	<u>\$ 31,358</u>	<u>\$ 5,360</u>	<u>\$ 150,483</u>

  

For the Nine Months Ended September 30,				
(Amounts in Thousands)				
	2024			2023
Segment reconciliation:				
Total segment operating income		\$ 169,210		\$ 150,483
Items not allocated at segment level:				
Other general and administrative expenses			83,115	77,048
Depreciation and amortization			10,316	10,449
Interest income			(2,805)	(977)
Interest expense			5,445	7,991
Income before income taxes		<u>\$ 73,139</u>		<u>\$ 55,972</u>

### 13. Significant Payors

The Company's revenue by payor type was as follows:

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,			
	2024		2023		2024		2023	
	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues
State, local and other governmental programs	\$ 116,702	54.2%	\$ 101,821	50.4%	\$ 337,458	53.0%	\$ 297,541	50.4%
Managed care organizations	93,321	43.3	93,584	46.4	281,732	44.3	272,758	46.2
Private pay	3,599	1.7	3,990	2.0	11,194	1.8	12,354	2.1
Commercial insurance	1,415	0.7	1,631	0.8	4,368	0.7	4,937	0.8
Other	396	0.1	856	0.4	1,501	0.2	2,637	0.5
Total personal care segment net service revenues	<u>\$ 215,433</u>	<u>100.0%</u>	<u>\$ 201,882</u>	<u>100.0%</u>	<u>\$ 636,253</u>	<u>100.0%</u>	<u>\$ 590,227</u>	<u>100.0%</u>

[Table of Contents](#)

**Hospice Segment**

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,			
	2024		2023		2024		2023	
	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues
Medicare	\$ 52,413	91.5%	\$ 47,313	89.1%	\$ 154,187	91.1%	\$ 137,432	90.2%
Commercial insurance	2,892	5.0	3,640	6.8	8,870	5.2	8,916	5.8
Managed care organizations	1,821	3.2	1,808	3.4	5,518	3.3	5,022	3.3
Other	183	0.3	360	0.7	627	0.4	1,044	0.7
Total hospice segment net service revenues	\$ 57,309	100.0%	\$ 53,121	100.0%	\$ 169,202	100.0%	\$ 152,414	100.0%

**Home Health Segment**

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,			
	2024		2023		2024		2023	
	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues
Medicare	\$ 12,036	70.6%	\$ 11,325	72.1%	\$ 36,216	69.6%	\$ 29,306	73.9%
Managed care organizations	4,215	24.7	3,445	21.9	13,291	25.6	8,239	20.8
Other	794	4.7	948	6.0	2,493	4.8	2,114	5.3
Total home health segment net service revenues	\$ 17,045	100.0%	\$ 15,718	100.0%	\$ 52,000	100.0%	\$ 39,659	100.0%

## Table of Contents

During the three and nine months ended September 30, 2024 and 2023, the Company derived a significant amount of its revenue from its operations in Illinois, New Mexico, New York, Ohio and Tennessee. The percentages of segment revenue for each of these significant states were as follows:

### Personal Care Segment

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,			
	2024		2023		2024		2023	
	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues
Illinois	\$ 111,916	51.9%	\$ 105,206	52.1%	\$ 330,265	51.9%	\$ 306,711	52.0%
New Mexico	28,962	13.4	28,347	14.0	86,573	13.6	84,969	14.3
New York <sup>(1)</sup>	21,406	9.9	22,989	11.4	68,239	10.7	68,910	11.7
All other states	53,149	24.8	45,340	22.5	151,176	23.8	129,637	22.0
Total personal care segment net service revenues	\$ 215,433	100.0%	\$ 201,882	100.0%	\$ 636,253	100.0%	\$ 590,227	100.0%

- (1) The selection process for CDPAP fiscal intermediaries has changed significantly in recent years and the program continues to be an area of focus for New York governmental authorities. As a result of the changes and uncertainty in the state, the Company determined that its New York personal care operations no longer fit its growth strategy and reached an agreement to divest these operations. See Note 4 to the Notes to Unaudited Condensed Consolidated Financial Statements, *Acquisition and Divestiture*, for additional details regarding our divestiture.

### Hospice Segment

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,			
	2024		2023		2024		2023	
	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues
Ohio	\$ 21,531	37.6%	\$ 18,916	35.6%	\$ 62,400	36.9%	\$ 55,363	36.3%
Illinois	13,289	23.2	12,477	23.5	38,544	22.8	34,750	22.8
New Mexico	6,951	12.1	7,619	14.3	21,361	12.6	23,688	15.5
All other states	15,538	27.1	14,109	26.6	46,897	27.7	38,613	25.4
Total hospice segment net service revenues	\$ 57,309	100.0%	\$ 53,121	100.0%	\$ 169,202	100.0%	\$ 152,414	100.0%

### Home Health Segment

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,			
	2024		2023		2024		2023	
	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues
New Mexico	\$ 8,090	47.4%	\$ 8,040	51.2%	\$ 24,166	46.5%	\$ 25,277	63.7%
Illinois	2,413	14.2	2,909	18.5	8,397	16.1	9,539	24.1
Tennessee	6,542	38.4	4,769	30.3	19,437	37.4	4,843	12.2
Total home health segment net service revenues	\$ 17,045	100.0%	\$ 15,718	100.0%	\$ 52,000	100.0%	\$ 39,659	100.0%

A substantial portion of the Company's revenue and accounts receivable are derived from services performed for federal, state and local governmental agencies. The personal care segment derives a significant amount of its net service revenues in Illinois, which represented 38.6%, and 38.9% of our net service revenues for the three months ended September 30, 2024, and 2023, respectively, and accounted for 38.5% and 39.2% of our net service revenues for the nine months ended September 30, 2024 and 2023, respectively. The Illinois Department on Aging, the largest payor program for the Company's Illinois personal care operations, accounted for 21.4% and 20.5% of the Company's net service revenues for the three months ended September 30, 2024 and 2023, respectively, and accounted for 21.1% and 21.2% of the Company's net service revenues for the nine months ended September 30, 2024 and 2023, respectively.

The related receivables due from the Illinois Department on Aging represented 21.7% and 25.8% of the Company's net accounts receivable at September 30, 2024 and December 31, 2023, respectively.

## 14. Subsequent Events

### *Fourth Amendment to Credit Agreement*

On October 22, 2024, the Company entered into a Fourth Amendment to Amended and Restated Credit Agreement (the “Fourth Amendment”) with certain lenders and Capital One, National Association, as a lender and as agent for all lenders, which further amended the Credit Agreement. The Fourth Amendment, among other things, (i) increased the Company’s revolving credit facility to an aggregate amount of \$650,000,000, (ii) increased the Company’s incremental loan facility to an aggregate amount of \$150,000,000, and (iii) extended the maturity date of the credit facility from July 30, 2026 to July 30, 2028.

### *New York Disposition Treatment*

In October 2024, the Company qualified for sale consideration of the New York Asset Sale. As a result, the Company will deconsolidate the results of its New York operations and record a gain on divestiture. The New York Asset Sale purchase price of up to \$23 million includes 50% cash consideration, paid out as an initial payment of \$4.6 million and \$6.9 million paid pro rata as a deferred payment as caregivers are transferred and 50% in the form of contingent consideration for the Company’s CDPAP business.

## ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

*You should read the following discussion together with our unaudited condensed consolidated financial statements and the related notes included elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements about our business and operations. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words like "believes," "belief," "expects," "plans," "anticipates," "intends," "projects," "estimates," "may," "might," "would," "should" and similar expressions are intended to be forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements are based on the beliefs and assumptions of our management based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the impact of macroeconomic conditions, including inflation and elevated interest rates, legislative and political developments, trade disruptions and the potential adverse effects of current geopolitical conditions; business disruptions due to inclement weather, natural disasters, acts of terrorism, pandemics, riots, civil insurrection or social unrest, looting, protests, strikes or street demonstrations; changes in operational and reimbursement processes and payment structures at the state or federal levels; changes in Medicaid, Medicare, other government programs and managed care organizations policies and payment rates, and the timeliness of reimbursements received under government programs; changes in, or our failure to comply with, existing, federal and state laws or regulations, or our failure to comply with new government laws or regulations on a timely basis; competition in the healthcare industry; the geographical concentration of our operations; changes in the case mix of consumers and payment methodologies; operational changes resulting from the assumption by managed care organizations of responsibility for managing and paying for our services to consumers; the nature and success of future financial and/or delivery system reforms; changes in estimates and judgments associated with critical accounting policies; our ability to maintain or establish new referral sources; our ability to renew significant agreements or groups of agreements; our ability to attract and retain qualified personnel; federal, state and city minimum wage pressure, including any failure of any governmental entity to enact a minimum wage offset and/or the timing of any such enactment; changes in payments and covered services due to the overall economic conditions and deficit reduction measures by federal and state governments, and our expectations regarding these changes; cost containment initiatives undertaken by federal and state governmental and other third-party payors; our ability to access financing through the capital and credit markets; our ability to meet debt service requirements and comply with covenants in debt agreements; our ability to integrate and manage our information systems; any security breaches, cyber-attacks, loss of data, or cybersecurity threats or incidents, and any actual or perceived failures to comply with legal requirements related to the privacy of confidential consumer data and other sensitive information; the size and growth of the markets for our services, including our expectations regarding the markets for our services; eligibility standards and limits on services imposed by state governmental agencies; the potential for litigation, audits and investigations; discretionary determinations by government officials; our ability to successfully implement our business model to grow our business; our ability to continue identifying, pursuing, consummating and integrating acquisition opportunities, including our ability to complete the Gentiva Acquisition and to realize the anticipated benefits from such acquisition, and expanding into new geographic markets; our ability to complete the New York Asset Sale; the impact of acquisitions and dispositions on our business, including the potential inability to realize the benefits of potential acquisitions; the effectiveness, quality and cost of our services; our ability to successfully execute our growth strategy; changes in tax rates; and various other matters, many of which are beyond our control. In addition, these forward-looking statements are subject to the risk factors set forth in Part I, Item 1A of our Annual Report on Form 10-K for the period ended December 31, 2023, filed with the SEC on February 27, 2024, as updated by the risk factors set forth in Part II, Item 1A of this Quarterly Report on Form 10-Q. You should carefully review all of these factors. Moreover, our business may be materially adversely affected by factors that are not currently known to us, by factors that we currently consider immaterial or by factors that are not specific to us, such as general economic conditions. These forward-looking statements were based on information, plans and estimates at the date of this report, and we assume no obligation to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes, except as may be required by law.*

### Overview

We are a home care services provider operating three segments: personal care, hospice and home health. Our services are principally provided in-home under agreements with federal, state and local government agencies, managed care organizations, commercial insurers and private individuals. Our consumers are predominantly "dual eligible," meaning they are eligible to receive both Medicare and Medicaid benefits. Managed care organizations accounted for 34.3% and 36.5% of our net service revenues during the three months ended September 30, 2024 and 2023, respectively, and 35.1% and 36.6% of our net service revenues during the nine months ended September 30, 2024 and 2023, respectively.

## [Table of Contents](#)

A summary of certain consolidated financial results is provided in the table below.

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	2024	2023	2024	2023
Net service revenues by segment:	(Amounts in Thousands)		(Amounts in Thousands)	
Personal care	\$ 215,433	\$ 201,882	\$ 636,253	\$ 590,227
Hospice	57,309	53,121	169,202	152,414
Home health	17,045	15,718	52,000	39,659
Total net service revenues	\$ 289,787	\$ 270,721	\$ 857,455	\$ 782,300
Net income	\$ 20,163	\$ 15,411	\$ 54,072	\$ 42,938

As of September 30, 2024, we provided our services in 22 states through 214 offices. We served approximately 80,000 and 62,000 discrete individuals, respectively, during the nine months ended September 30, 2024 and 2023. Our personal care segment also includes staffing services, with clients including assisted living facilities, nursing homes and hospice facilities.

### **Acquisitions**

In addition to our organic growth, we have grown through acquisitions that have expanded our presence in current markets, with the goal of having all three levels of in-home care in our markets or facilitating our entry into new markets where in-home care has been moving to managed care organizations.

On January 1, 2023, we completed the acquisition of CareStaff for approximately \$1.0 million, with funding provided by available cash. With the purchase of CareStaff, the Company expanded its personal care services in Florida.

On August 1, 2023, we completed the acquisition of Tennessee Quality Care for approximately \$111.2 million, with funding primarily provided by drawing on the Company's revolving credit facility. With the purchase of Tennessee Quality Care, the Company expanded its services within its hospice and home health segments to Tennessee.

On March 9, 2024, we completed our acquisition of the operations of Upstate for \$0.4 million, with funding provided by available cash. With the purchase of Upstate, the Company expanded its personal care services segment in South Carolina.

On June 8, 2024, we entered into the Gentiva Purchase Agreement to acquire the personal care operations of Gentiva, consisting of equity interests and certain assets and liabilities, for a purchase price of approximately \$350.0 million, payable in full in cash at the closing, subject to typical adjustments for working capital and other customary items. The acquired business operates in Arizona, Arkansas, California, Missouri, North Carolina, Tennessee and Texas, and serves approximately 16,000 patients. The Company expects to close this acquisition following completion of regulatory approvals and subject to customary closing conditions and will fund this acquisition through the Company's existing revolving credit facility and a portion of the net proceeds from the Public Offering.

### **New York Asset Sale**

On May 21, 2024, we entered into the New York Asset Sale. The Company entered into a consulting agreement as the transfer of clients and caregivers and payment for assets pursuant to the New York Asset Sale is occurring over time as regulatory approvals are received, coordination of the transfer of clients and caregivers occurs, and the change of control takes place. In connection with this transaction, the Company will cease operations in New York. See Note 14 to the Notes to Unaudited Condensed Consolidated Financial Statements, *Subsequent Events*, for additional details regarding the New York Asset Sale.

### **Recruiting**

As the labor market continues to be tight and unemployment remains at low levels, the competition for new caregivers, including skilled healthcare staff, and support staff continues to be significant. In recent periods, the United States economy has experienced, and may continue to experience, significant inflationary pressures. To the extent that we continue to experience a shortage of caregivers, it may hinder our ability to fully meet the continuing demand for both our non-clinical and clinical services.

[Table of Contents](#)

**Revenue by Payor and Significant States**

Our payors are principally federal, state and local governmental agencies and managed care organizations. The federal, state and local programs under which the agencies operate are subject to legislative and budgetary changes and other risks that can influence reimbursement rates. We are experiencing a transition of business from government payors to managed care organizations, which we believe aligns with our emphasis on coordinated care and the reduction of the need for acute care.

Our revenue by payor and significant states by segment were as follows:

<i>Personal Care Segment</i>	For the Three Months Ended September 30,				For the Nine Months Ended September 30,			
	2024		2023		2024		2023	
	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues
State, local and other governmental programs	\$ 116,702	54.2%	\$ 101,821	50.4%	\$ 337,458	53.0%	\$ 297,541	50.4%
Managed care organizations	93,321	43.3	93,584	46.4	281,732	44.3	272,758	46.2
Private pay	3,599	1.7	3,990	2.0	11,194	1.8	12,354	2.1
Commercial insurance	1,415	0.7	1,631	0.8	4,368	0.7	4,937	0.8
Other	396	0.1	856	0.4	1,501	0.2	2,637	0.5
Total personal care segment net service revenues	\$ 215,433	100.0%	\$ 201,882	100.0%	\$ 636,253	100.0%	\$ 590,227	100.0%
Illinois	\$ 111,916	51.9%	\$ 105,206	52.1%	\$ 330,265	51.9%	\$ 306,711	52.0%
New Mexico	28,962	13.4	28,347	14.0	86,573	13.6	84,969	14.3
New York <sup>(1)</sup>	21,406	9.9	22,989	11.4	68,239	10.7	68,910	11.7
All other states	53,149	24.8	45,340	22.5	151,176	23.8	129,637	22.0
Total personal care segment net service revenues	\$ 215,433	100.0%	\$ 201,882	100.0%	\$ 636,253	100.0%	\$ 590,227	100.0%

- (1) The selection process for CDPAP fiscal intermediaries has changed significantly in recent years and the program continues to be an area of focus for New York governmental authorities. As a result of the changes and uncertainty in the state, the Company determined that its New York personal care operations no longer fit its growth strategy and reached an agreement to divest these operations. See Note 4 to the Notes to Unaudited Condensed Consolidated Financial Statements, *Acquisition and Divestiture*, for additional details regarding our divestiture.

<i>Hospice Segment</i>	For the Three Months Ended September 30,				For the Nine Months Ended September 30,			
	2024		2023		2024		2023	
	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues
Medicare	\$ 52,413	91.5%	\$ 47,313	89.1%	\$ 154,187	91.1%	\$ 137,432	90.2%
Commercial insurance	2,892	5.0	3,640	6.8	8,870	5.2	8,916	5.8
Managed care organizations	1,821	3.2	1,808	3.4	5,518	3.3	5,022	3.3
Other	183	0.3	360	0.7	627	0.4	1,044	0.7
Total hospice segment net service revenues	\$ 57,309	100.0%	\$ 53,121	100.0%	\$ 169,202	100.0%	\$ 152,414	100.0%
Ohio	\$ 21,531	37.6%	\$ 18,916	35.6%	\$ 62,400	36.9%	\$ 55,363	36.3%
Illinois	13,289	23.2	12,477	23.5	38,544	22.8	34,750	22.8
New Mexico	6,951	12.1	7,619	14.3	21,361	12.6	23,688	15.5
All other states	15,538	27.1	14,109	26.6	46,897	27.7	38,613	25.4
Total hospice segment net service revenues	\$ 57,309	100.0%	\$ 53,121	100.0%	\$ 169,202	100.0%	\$ 152,414	100.0%

[Table of Contents](#)

<i>Home Health Segment</i>	For the Three Months Ended September 30,				For the Nine Months Ended September 30,			
	2024		2023		2024		2023	
	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues	Amount (in Thousands)	% of Segment Net Service Revenues
Medicare	\$ 12,036	70.6%	\$ 11,325	72.1%	\$ 36,216	69.6%	\$ 29,306	73.9%
Managed care organizations	4,215	24.7	3,445	21.9	13,291	25.6	8,239	20.8
Other	794	4.7	948	6.0	2,493	4.8	2,114	5.3
Total home health segment net service revenues	\$ 17,045	100.0%	\$ 15,718	100.0%	\$ 52,000	100.0%	\$ 39,659	100.0%
New Mexico	\$ 8,090	47.4%	\$ 8,040	51.2%	\$ 24,166	46.5%	\$ 25,277	63.7%
Illinois	2,413	14.2	2,909	18.5	8,397	16.1	9,539	24.1
Tennessee	6,542	38.4	4,769	30.3	19,437	37.4	4,843	12.2
Total home health segment net service revenues	\$ 17,045	100.0%	\$ 15,718	100.0%	\$ 52,000	100.0%	\$ 39,659	100.0%

The personal care segment derives a significant amount of its net service revenues in Illinois, which represented 38.6% and 38.9% of our net service revenues for the three months ended September 30, 2024 and 2023, respectively, and accounted for 38.5% and 39.2% of our net service revenues for the nine months ended September 30, 2024 and 2023, respectively.

A significant amount of our net service revenues are derived from one payor, the Illinois Department on Aging, the largest payor program for our Illinois personal care operations, which accounted for 21.4% and 20.5% of our net service revenues for the three months ended September 30, 2024 and 2023, respectively, and accounted for 21.1% and 21.2% of the Company's net service revenues for the nine months ended September 30, 2024 and 2023, respectively.

**Changes in Reimbursement Rates**

*Illinois*

The City of Chicago requires the Chicago minimum wage to be adjusted annually based on increases in the Consumer Price Index ("CPI"), subject to a cap and other requirements. On July 1, 2024, the rate was adjusted to \$16.20 based on the increase in the CPI.

The Illinois fiscal year 2023 budget included an increase of hourly rates for in-home care services to \$25.66, to be effective January 1, 2023. This increase offsets the \$0.40 increase in Chicago minimum wage that occurred on July 1, 2022. In addition, CMS approved a waiver amendment proposal submitted by the Illinois Department of Healthcare and Family Services with regard to its Persons who are Elderly program, further increasing in-home care rates to \$26.92, effective March 1, 2023.

The Illinois Medicaid omnibus legislation passed in June 2023 included an increase in hourly rates for in-home care services to \$28.07, which took effect on January 1, 2024 and required a minimum wage rate of \$17.00 per hour. CMS approved an amendment to the Illinois HCBS Waiver for Persons Who are Elderly, which included the rate increase for in-home care services to \$28.07, effective January 1, 2024.

The Illinois fiscal year 2025 budget includes an increase in hourly rates for in-home care services to \$29.63, to take effect January 1, 2025, subject to federal approval. This rate supports the required minimum wage of \$18.00 per hour for direct service workers.

Our business will benefit from the rate increases noted above as planned for 2025, but there is no assurance that there will be additional rate increases in Illinois for fiscal years beyond fiscal year 2025 to offset increases to minimum wage, and our financial performance will be adversely impacted for any periods in which an additional offsetting reimbursement rate increase is not in effect.



## ***Impact of Changes in Medicare and Medicaid Reimbursement***

### *Hospice*

Hospice services provided to Medicare beneficiaries are paid under the Medicare Hospice Prospective Payment System, under which CMS sets a daily rate for each day a patient is enrolled in the hospice benefit. CMS updates these rates each federal fiscal year. Effective October 1, 2024, CMS increased hospice payment rates by 2.9%. This reflects a 3.4% market basket increase and a negative 0.5 percentage point productivity adjustment. Hospices that do not satisfy quality reporting requirements are subject to a 4-percentage point reduction to the market basket update.

Overall payments made by Medicare to each hospice provider number are subject to an inpatient cap and an aggregate cap, which is set each federal fiscal year. The inpatient cap limits the number of days of inpatient care to no more than 20% of total patient care days. The aggregate cap, which limits the total Medicare reimbursement that a hospice may receive based on an annual per-beneficiary cap amount and the number of Medicare patients served, was updated to \$34,465.34 for federal fiscal year 2025. If a hospice's Medicare payments exceed its inpatient or aggregate caps, it must repay Medicare the excess amount.

### *Home Health*

Home health services provided to Medicare beneficiaries are paid under the Medicare Home Health Prospective Payment System ("HHPPS"), which uses national, standardized 30-day period payment rates for periods of care that meet a certain threshold of home health visits (periods of care that do not meet the visit threshold are paid a per-visit payment rate for providing care). Although payment is made for each 30-day period, the HHPPS permits continuous 60-day certification periods through which beneficiaries are verified as eligible for the home health benefit. The daily home health payment rate is adjusted for case-mix and area wage levels. CMS uses the Patient-Driven Groupings Model ("PDGM") as the case-mix classification model to place periods of care into payment categories, classifying patients based on clinical characteristics and their resource needs. An outlier adjustment may be paid for periods of care where costs exceed a specific threshold amount.

CMS updates the HHPPS payment rates each calendar year. For calendar year 2024, CMS estimates that Medicare payments to home health agencies will increase by 0.8%. This is based on a home health payment update percentage of 3.0, which reflects a 3.3% market basket update reduced by a productivity adjustment of negative 0.3 percentage points, and an estimated 2.6% decrease associated with the transition to the PDGM, among other changes. Home health providers that do not comply with quality data reporting requirements are subject to a 2-percentage point reduction to their market basket update. In addition, Medicare requires home health agencies to submit a one-time Notice of Admission ("NOA") for each patient that establishes that the beneficiary is under a Medicare home health period of care. Failure to submit the NOA within five calendar days from the start of care will result in a reduction to the 30-day period payment amount for each day from the start of care date until the date the NOA is submitted.

CMS began implementing a nationwide expansion of the Home Health Value-Based Purchasing ("HHVBP") Model in 2022. Under the HHVBP Model, home health agencies receive increases or decreases to their Medicare fee-for-service payments of up to 5% based on performance against specific quality measures relative to the performance of other home health providers. Data collected in each performance year will impact Medicare payments two years later. Calendar year 2023 was the first performance year under the expanded HHVBP Model, which will affect payments in calendar year 2025.

In certain states, payment of claims may be impacted by the Review Choice Demonstration for Home Health Services, a program intended to identify and prevent fraud, reduce the number of Medicare appeals and improve provider compliance with Medicare program requirements. The program currently applies to home health agencies in certain states, including Illinois, Ohio, Oklahoma, North Carolina, Florida and Texas. Providers in states subject to the Review Choice Demonstration for Home Health Services may initially select either pre-claim review or post-payment review. Previously, providers could also opt for minimal post-payment review with a 25% payment reduction, but CMS has removed this option. Providers that had selected the minimal post-payment review option transitioned to pre-claim or post-payment review in mid-July. Home health agencies that maintain high compliance levels are eligible for additional options that may be less burdensome. This program has not had a material impact on our results of operations or financial position.

## [Table of Contents](#)

The IMPACT Act required the Department of Health and Human Services (“HHS”), together with the Medicare Payment Advisory Commission (“MedPAC”), to consider and propose a unified payment system for post-acute care services provided by home health agencies, inpatient rehabilitation facilities, skilled nursing facilities and long-term care hospitals. A unified post-acute care payment system would pay post-acute care providers under a single framework according to a patient’s characteristics, rather than based on the post-acute care setting where the patient receives treatment. As required under the statute, CMS and the HHS Office of the Assistant Secretary for Planning and Evaluation issued a report in July 2022 presenting a prototype for a unified post-acute care payment model, and MedPAC submitted a report to Congress in June 2023 evaluating a prototype design. Although both CMS and MedPAC concluded that designing a unified payment system is feasible, CMS noted that universal implementation of a unified payment system would require congressional action and MedPAC cautioned that implementation would be complex. Due to the agency resources required to implement a unified model, MedPAC noted that CMS may consider smaller-scale site-neutral policies to address some of the overlap in patients treated in different settings and highlighted that recent changes to various post-acute care payment systems address some of the concerns underlying the push for a unified model.

### ***New York Consumer Directed Personal Assistance Program (“CDPAP”)***

The CDPAP is a self-directed care alternative program that allows eligible individuals who need help with activities of daily living or skilled nursing services to choose their caregivers. We provide support services as a CDPAP fiscal intermediary. The Company recognized approximately \$9.3 million and \$30.3 million in revenue from the program for the three and nine months ended September 30, 2024, respectively and \$10.2 million and \$30.6 million in revenue from the program for the three and nine months ended September 30, 2023, respectively.

The selection process for CDPAP fiscal intermediaries has changed significantly in recent years and the program continues to be an area of focus for New York governmental authorities. As a result of the changes and uncertainty in the state, the Company determined that its New York personal care operations no longer fit its growth strategy and reached an agreement to divest these operations. See Note 4 to the Notes to Unaudited Condensed Consolidated Financial Statements, Acquisition and Divestiture, for additional details regarding our divestiture.

### ***CMS Final Rule: “Ensuring Access to Medicaid Services”***

On April 22, 2024, CMS announced a final rule intended to improve access to services and quality of care for Medicaid beneficiaries across fee-for-service and managed care delivery systems. The final rule includes significant provisions related to HCBS, including the “80/20” or “payment adequacy” requirement, which will require states to ensure that at least 80% of all Medicaid payments a provider receives for homemaker, home health aide, and personal care services, less certain excluded costs, under specified programs are spent on total compensation (including benefits) for direct care workers furnishing these services, rather than administrative overhead or profit, subject to limited exceptions. States are required to ensure compliance with the 80/20 requirement by mid-2030. The final rule made a number of technical changes to the definitions used in calculating compliance that clarified or narrowed the revenue covered by the calculation and clarified or expanded the payments to workers that are counted in satisfying the requirement, which combined to make compliance less onerous to providers.

The final rule includes several other measures intended to promote transparency and enhance quality and access to services, including a variety of reporting requirements for states. Given the very long implementation period and the likelihood of further changes as a result of litigation, administration changes, further rule-making and state changes in response to the final rule, it is premature to predict the ultimate impact of the final rule on our business.

### ***Components of our Statements of Income***

#### *Net Service Revenues*

We generate net service revenues by providing our services directly to consumers and primarily on an hourly basis in our personal care segment, on a daily basis in our hospice segment and on an episodic basis in our home health segment. We receive payment for providing such services from our private consumers and payors, including federal, state and local governmental agencies, managed care organizations and commercial insurers.

In our personal care segment, net service revenues are principally provided based on authorized hours, determined by the relevant agency, at an hourly rate, which is either contractual or fixed by legislation, and are recognized at the time services are rendered. In our hospice segment, net service revenues are provided based on daily rates for each of the levels of care and are recognized as services are provided. In our home health segment, net service revenues are based on an episodic basis at a stated rate and recognized based on the number of days elapsed during a period of care within the reporting period. We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record revenues.

## [Table of Contents](#)

### *Cost of Service Revenues*

We incur direct care wages, payroll taxes and benefit-related costs in connection with providing our services. We also provide workers' compensation and general liability coverage for our employees. Employees are also reimbursed for their travel time and related travel costs in certain instances.

### *General and Administrative Expenses*

Our general and administrative expenses include our costs for operating our network of local agencies and our administrative offices. Our agency expenses consist of costs for supervisory personnel, our community care supervisors and office administrative costs. Personnel costs include wages, payroll taxes and employee benefits. Facility costs include rents, utilities, and postage, telephone and office expenses. Our corporate and support center expenses include costs for accounting, information systems, human resources, billing and collections, contracting, marketing and executive leadership. These expenses consist of compensation, including stock-based compensation, payroll taxes, employee benefits, legal, accounting and other professional fees, travel, general insurance, rents, provision for doubtful accounts and related facility costs. Expenses related to streamlining our operations such as costs related to terminated employees, termination of professional services relationships, other contract termination costs and asset write-offs are also included in general and administrative expenses.

### *Depreciation and Amortization Expenses*

Depreciable assets consist principally of furniture and equipment, network administration and telephone equipment and operating system software. Depreciable and leasehold assets are depreciated or amortized on a straight-line method over their useful lives or, if less and if applicable, their lease terms. We amortize our intangible assets with finite lives, consisting of customer and referral relationships, trade names, trademarks and non-competition agreements, using straight line or accelerated methods based upon their estimated useful lives.

### *Interest Expense*

Interest expense is reported when incurred and principally consists of interest and unused credit line fees on the credit facility.

### *Income Tax Expense*

All of our income is from domestic sources. We incur state and local taxes in the states in which we operate. The effective income tax rates were 26.1% and 23.8% for the three months ended September 30, 2024 and 2023, respectively. The effective income tax rates were 26.1% and 23.3% for the nine months ended September 30, 2024 and 2023, respectively. The difference between our federal statutory rate of 21% and our effective income tax rates is principally due to the inclusion of state taxes and non-deductible compensation, partially offset by the use of federal employment tax credits.

**Results of Operations — Consolidated**

Three Months Ended September 30, 2024 Compared to Three Months Ended September 30, 2023

The following table sets forth, for the periods indicated, our unaudited condensed consolidated results of operations.

	For the Three Months Ended September 30,				Change	
	2024		2023		Amount	%
	Amount	% Of Net Service Revenues	Amount	% Of Net Service Revenues		
	(Amounts in Thousands, Except Percentages)					
Net service revenues	\$ 289,787	100.0 %	\$ 270,721	100.0 %	\$ 19,066	7.0 %
Cost of service revenues	197,583	68.2	183,991	68.0	13,592	7.4
Gross profit	92,204	31.8	86,730	32.0	5,474	6.3
General and administrative expenses	62,805	21.7	60,271	22.3	2,534	4.2
Depreciation and amortization	3,446	1.2	3,620	1.3	(174)	(4.8)
Total operating expenses	66,251	22.9	63,891	23.6	2,360	3.7
Operating income	25,953	8.9	22,839	8.4	3,114	13.6
Interest income	(1,908)	(0.7)	(580)	(0.2)	(1,328)	228.8
Interest expense	573	0.2	3,199	1.2	(2,626)	(82.1)
Total interest expense, net	(1,335)	(0.5)	2,619	1.0	(3,954)	(151.0)
Income before income taxes	27,288	9.4	20,220	7.4	7,068	35.0
Income tax expense	7,125	2.5	4,809	1.8	2,316	48.2
Net income	\$ 20,163	6.9 %	\$ 15,411	5.7 %	\$ 4,752	30.8 %

Net service revenues increased by 7.0% to \$289.8 million for the three months ended September 30, 2024 compared to \$270.7 million for the three months ended September 30, 2023. Revenue increased by \$13.6 million in our personal care segment, \$4.2 million in our hospice segment and \$1.3 million in our home health segment during the three months ended September 30, 2024, compared to the same period in 2023. The increase in our personal care segment was mainly due to an increase in revenues per billable hour for the three months ended September 30, 2024. The increase in our hospice and home health segments was primarily due to the acquisition of the operations of Tennessee Quality Care on August 1, 2023.

Gross profit, expressed as a percentage of net service revenues, decreased to 31.8% for the three months ended September 30, 2024, compared to 32.0% for the same period in 2023, due to slightly lower margins in our personal care and hospice segments as the result of increases to direct care wages.

General and administrative expenses increased to \$62.8 million for the three months ended September 30, 2024, as compared to \$60.3 million for the three months ended September 30, 2023. The increase in general and administrative expenses was primarily due to the Tennessee Quality Care acquisition that resulted in an increase in administrative employee wages, bonus, taxes and benefit costs of \$2.5 million. General and administrative expenses, expressed as a percentage of net service revenues, decreased to 21.7% for the three months ended September 30, 2024, from 22.3% for the three months ended September 30, 2023.

Interest expense decreased to \$0.6 million for the three months ended September 30, 2024 from \$3.2 million for the three months ended September 30, 2023. The decrease in interest expense was primarily due to decreased amounts held under our credit facility for the three months ended September 30, 2024 compared to the three months ended September 30, 2023. Interest income increased \$1.3 million due to an increase in cash investment into interest bearing accounts from the Public Offering.

All of our income is from domestic sources. We incur state and local taxes in states in which we operate. The effective income tax rate was 26.1% and 23.8% for the three months ended September 30, 2024 and 2023, respectively. Our higher effective income tax rate for the three months ended September 30, 2024 was principally due to a lower excess tax benefit as well as a lower benefit from the use of federal employment tax credits. For the three months ended September 30, 2024 and 2023, the excess tax benefit and federal employment tax credits were 3.1% and 5.0%, respectively.

[Table of Contents](#)

*Nine Months Ended September 30, 2024 Compared to Nine Months Ended September 30, 2023*

The following table sets forth, for the periods indicated, our unaudited condensed consolidated results of operations.

	For the Nine Months Ended September 30,				Change	
	2024		2023		Amount	%
	Amount	% Of Net Service Revenues	Amount	% Of Net Service Revenues		
(Amounts in Thousands, Except Percentages)						
Net service revenues	\$ 857,455	100.0 %	\$ 782,300	100.0 %	\$ 75,155	9.6 %
Cost of service revenues	583,916	68.1	534,837	68.4	49,079	9.2
Gross profit	273,539	31.9	247,463	31.6	26,076	10.5
General and administrative expenses	187,444	21.9	174,028	22.2	13,416	7.7
Depreciation and amortization	10,316	1.2	10,449	1.3	(133)	(1.3)
Total operating expenses	197,760	23.1	184,477	23.5	13,283	7.2
Operating income	75,779	8.8	62,986	8.0	12,793	20.3
Interest income	(2,805)	(0.3)	(977)	(0.1)	(1,828)	187.1
Interest expense	5,445	0.6	7,991	1.0	(2,546)	(31.9)
Total interest expense, net	2,640	0.3	7,014	0.9	(4,374)	(62.4)
Income before income taxes	73,139	8.5	55,972	7.1	17,167	30.7
Income tax expense	19,067	2.2	13,034	1.7	6,033	46.3
Net income	\$ 54,072	6.3 %	\$ 42,938	5.4 %	\$ 11,134	25.9 %

Net service revenues increased by 9.6% to \$857.5 million for the nine months ended September 30, 2024 compared to \$782.3 million for the nine months ended September 30, 2023. Net service revenue increased by \$46.0 million in our personal care segment, by \$16.8 million in our hospice segment and by \$12.3 million in our home health segment during the nine months ended September 30, 2024, compared to the same period in 2023. During the nine months ended September 30, 2024, the increase in our personal care segment net service revenues was primarily due to an increase in revenues per billable hour, attributable to the rate increases discussed above, compared to the same period in 2023. The increase in net service revenues in our hospice and home health segments is primarily attributable to the acquisition of the operations of Tennessee Quality Care on August 1, 2023.

Gross profit, expressed as a percentage of net service revenues, increased to 31.9% for the nine months ended September 30, 2024 compared to 31.6% for the nine months ended September 30, 2023 due to an increase in net service revenues and gross profit in our personal care segment and higher margin in our hospice segment due to the acquisition of the operations of Tennessee Quality Care on August 1, 2023.

General and administrative expenses increased to \$187.4 million for the nine months ended September 30, 2024 as compared to \$174.0 million for the nine months ended September 30, 2023. The increase in general and administrative expenses was primarily due to the Tennessee Quality Care acquisitions that resulted in an increase in administrative employee wages, bonus, taxes and benefit costs of \$8.4 million and an increase in acquisition-related expense of \$2.8 million. General and administrative expenses, expressed as a percentage of net service revenues, decreased to 21.9% for the nine months ended September 30, 2024, from 22.2% for the nine months ended September 30, 2023.

Interest expense decreased to \$5.4 million for the nine months ended September 30, 2024, as compared to \$8.0 million for the nine months ended September 30, 2023. The decrease in interest expense was primarily due to decreased amounts held under our credit facility for the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023. Interest income increased \$1.8 million due to an increase in cash investment into interest bearing accounts from the Public Offering.

All of our income is from domestic sources. We incur state and local taxes in states in which we operate. The effective income tax rate was 26.1% and 23.3% for the nine months ended September 30, 2024 and 2023, respectively. Our higher effective income tax rate for the nine months ended September 30, 2024 was principally due to a lower excess tax benefit as well as a lower benefit from the use of federal employment tax credits. For the nine months ended September 30, 2024 and 2023, the excess tax benefit and federal employment tax credits were 3.1% and 5.8%, respectively.

**Results of Operations – Segments**

The following tables and related analysis summarize our operating results and business metrics by segment:

**Personal Care Segment**

	For the Three Months Ended September 30,						For the Nine Months Ended September 30,					
	2024		2023		Change		2024		2023		Change	
	Amount	% of Segment Net Service Revenues	Amount	% of Segment Net Service Revenues	Amount	%	Amount	% of Segment Net Service Revenues	Amount	% of Segment Net Service Revenues	Amount	%
<b>Operating Results</b>												
Net service revenues	\$ 215,433	100.0%	\$ 201,882	100.0%	\$ 13,551	6.7%	\$ 636,253	100.0%	\$ 590,227	100.0%	\$ 46,026	7.8%
Cost of services revenues	156,273	72.5	145,808	72.2	10,465	7.2	461,564	72.5	428,163	72.5	33,401	7.8
Gross profit	59,160	27.5	56,074	27.8	3,086	5.5	174,689	27.5	162,064	27.5	12,625	7.8
General and administrative expenses	17,489	8.1	16,096	8.0	1,393	8.7	49,907	7.8	48,299	8.2	1,608	3.3
Segment operating income	\$ 41,671	19.3%	\$ 39,978	19.8%	\$ 1,693	4.2%	\$ 124,782	19.7%	\$ 113,765	19.3%	\$ 11,017	9.7%
<b>Business Metrics (Actual Numbers, Except Billable Hours in Thousands)</b>												
Locations at period end							153		156			
Average billable census * (1)	37,701		38,590		(889)	(2.3)%	37,803		38,668		(865)	(2.2)%
Billable hours * (2)	7,776		7,690		86	1.1	23,098		22,964		134	0.6
Average billable hours per census per month * (2)	68.7		66.3		2.4	3.6	67.8		65.8		2.0	3.0
Billable hours per business day * (2)	117,822		118,314		(492)	(0.4)	117,849		117,765		84	0.1
Revenues per billable hour * (2)	\$ 27.66		\$ 26.18		\$ 1.48	5.7%	\$ 27.49		\$ 25.58		\$ 1.91	7.5%
Same store growth revenue % * (3)	6.8%		13.9%				8.4%		12.5%			

- Average billable census is the number of unique clients receiving a billable service during the year and is the total census divided by months in operation during the period.
- Billable hours is the total number of hours served to clients during the period. Average billable hours per census per month is billable hours divided by average billable census. Billable hours per day is total billable hours divided by the number of business days in the period. Revenues per billable hour is revenue, attributed to billable bonus hours, divided by billable hours.
- Same store growth reflects the change in year-over-year revenue for the same store base. We define the same store base to include those stores open for at least 52 full weeks. This measure highlights the performance of existing stores, while excluding the impact of acquisitions, new store openings and closures and ARPA associated revenue from this calculation.

\* Management deems these metrics to be key performance indicators. Management uses these metrics to monitor our performance, both in our existing operations and acquisitions. Many of these metrics serve as the basis of reported revenues and assessment of these provide direct correlation to the results of operations from period to period and facilitate comparison with the results of our peers. Historical trends established in these metrics can be used to evaluate current operating results, identify trends affecting our business, determine the allocation of resources and assess the quality and potential variability of our cash flows and earnings. We believe they are useful to investors in evaluating and understanding our business but should not be used solely in assessing the Company's performance. These key performance indicators should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented herein to fully evaluate and understand the business as a whole. These measures may not be comparable to similarly titled performance indicators used by other companies.

The personal care segment derives a significant amount of its net service revenues from operations in Illinois, which represented 38.6% and 38.9% of our net service revenues for the three months ended September 30, 2024 and 2023, respectively, and accounted for 38.5% and 39.2% of our net service revenues for the nine months ended September 30, 2024 and 2023, respectively. One payor, the Illinois Department on Aging, accounted for 21.4% and 20.5% of net service revenues for the three months ended September 30, 2024 and 2023, respectively, and accounted for 21.1% and 21.2% of net service revenues for the nine months ended September 30, 2024 and 2023, respectively.

Net service revenues from state, local and other governmental programs accounted for 54.2% and 50.4% of personal care segment net service revenues for the three months ended September 30, 2024 and 2023, respectively. Managed care organizations accounted for 43.3% and 46.4% of personal care segment net service revenues for the three months ended September 30, 2024 and 2023, respectively, with commercial insurance, private pay and other payors accounting for the remainder of personal care segment net service revenues. Net service revenues from state, local and other governmental programs accounted for 53.0% and 50.4% of net service revenues for the nine months ended September 30, 2024 and 2023, respectively. Managed care organizations accounted for 44.3% and 46.2% of personal care segment net service revenues for the nine months ended September 30, 2024 and 2023, respectively, with commercial insurance, private pay and other payors accounting for the remainder of net service revenues.

## Table of Contents

Personal care segment net service revenues increased by 6.7% and 7.8% for the three and nine months ended September 30, 2024, respectively, compared to the three and nine months ended September 30, 2023. Net service revenues included a 5.7% and 7.5% increase in revenues per billable hour for the three and nine months ended September 30, 2024, respectively, mainly attributed to rate increases discussed above, as compared to the three and nine months ended September 30, 2023.

Gross profit, expressed as a percentage of net service revenues, decreased to 27.5% for the three months ended September 30, 2024 from 27.8% for the three months ended September 30, 2023. The decrease was mainly attributed to increases in direct care wages, taxes and benefit costs for the three months ended September 30, 2024. Gross profit, expressed as a percentage of net service revenues, was 27.5% for both the nine months ended September 30, 2024 and the nine months ended September 30, 2023.

The personal care segment's general and administrative expenses primarily consist of administrative employee wages, taxes and benefit costs, rent, information technology and office expenses. General and administrative expenses, expressed as a percentage of net service revenues, were 8.1% and 8.0% for the three months ended September 30, 2024 and 2023, respectively, and 7.8% and 8.2% for the nine months ended September 30, 2024 and 2023, respectively.

## Hospice Segment

	For the Three Months Ended September 30,						For the Nine Months Ended September 30,					
	2024		2023		Change		2024		2023		Change	
	Amount	% of Segment Net Service Revenues	Amount	% of Segment Net Service Revenues	Amount	%	Amount	% of Segment Net Service Revenues	Amount	% of Segment Net Service Revenues	Amount	%
	(Amounts in Thousands, Except Percentages)						(Amounts in Thousands, Except Percentages)					
<b>Operating Results</b>												
Net service revenues	\$ 57,309	100.0 %	\$ 53,121	100.0 %	\$ 4,188	7.9 %	\$ 169,202	100.0 %	\$ 152,414	100.0 %	\$ 16,788	11.0 %
Cost of services revenues	30,469	53.2	28,155	53.0	2,314	8.2	89,166	52.7	82,028	53.8	7,138	8.7
Gross profit	26,840	46.8	24,966	47.0	1,874	7.5	80,036	47.3	70,386	46.2	9,650	13.7
General and administrative expenses	14,070	24.6	13,246	24.9	824	6.2	40,975	24.2	39,028	25.6	1,947	5.0
Segment operating income	\$ 12,770	22.2 %	\$ 11,720	22.1 %	\$ 1,050	9.0 %	\$ 39,061	23.1 %	\$ 31,358	20.6 %	\$ 7,703	24.6 %
<b>Business Metrics (Actual Numbers)</b>												
Locations at period end							38		40			
Admissions * (1)	3,105		3,176		(71)	-2.2 %	9,771		9,576		195	2.0 %
Average daily census * (2)	3,534		3,453		81	2.3	3,457		3,426		31	0.9
Average discharge length of stay * (3)	96		97		(1)	(0.8)	93		93		(0)	(0.3)
Patient days * (4)	325,160		311,454		13,706	4.4	947,241		892,507		54,734	6.1
Revenue per patient day * (5)	\$ 176.25		\$ 175.19		\$ 1.06	0.6 %	\$ 179.43		\$ 175.23		\$ 4.20	2.4 %
Organic growth												
- Revenue * (6)	3.5 %		3.1 %				5.2 %		1.5 %			
- Average daily census * (6)	2.1 %		(0.9) %				0.8 %		0.8 %			

- (1) Represents referral process and new patients on service during the period.
- (2) Average daily census is total patient days divided by the number of days in the period.
- (3) Average length of stay is the average number of days a patient is on service, calculated upon discharge, and is total patient days divided by total discharges in the period.
- (4) Patient days is days of service for all patients in the period.
- (5) Revenue per patient day is hospice revenue divided by the number of patient days in the period.
- (6) Revenue organic growth and average daily census organic growth reflect the change in year-over-year revenue and average daily census for the same store base. We define the same store base to include those stores open for at least 52 full weeks. These measures highlight the performance of existing stores, while excluding the impact of acquisitions, new store openings and closures.

\* Management deems these metrics to be key performance indicators. Management uses these metrics to monitor our performance, both in our existing operations and acquisitions. Many of these metrics serve as the basis of reported revenues and assessment of these provide direct correlation to the results of operations from period to period and facilitate comparison with the results of our peers. Historical trends established in these metrics can be used to evaluate current operating results, identify trends affecting our business, determine the allocation of resources and assess the quality and potential variability of our cash flows and earnings. We believe they are useful to investors in evaluating and understanding our business but should not be used solely in assessing the Company's performance. These key performance indicators should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented herein to fully evaluate and understand the business as a whole. These measures may not be comparable to similarly titled performance indicators used by other companies.



## Table of Contents

The hospice segment generates net service revenues by providing care to patients with a life expectancy of six months or less, as well as related services for their families. Hospice offers four levels of care, as defined by Medicare, to meet the varying needs of patients and their families. The four levels of hospice include routine home care, continuous home care, general inpatient care and respite care. Our hospice segment principally provides routine home care and continuous home care services, and with the JourneyCare acquisition, expanded into providing general inpatient care services. In our hospice segment, net service revenues from Medicare accounted for 91.5% and 89.1% of total hospice segment net service revenues for the three months ended September 30, 2024 and 2023, respectively, and 91.1% and 90.2% for the nine months ended September 30, 2024 and 2023, respectively. Net service revenues from managed care organizations accounted for 3.2% and 3.4% of total hospice segment net service revenues for each the three months ended September 30, 2024 and 2023, respectively, and 3.3% and 3.3% for the nine months ended September 30, 2024 and 2023, respectively.

Hospice net service revenues increased by \$4.2 million and \$16.8 million for the three and nine months ended September 30, 2024, respectively, compared to the three and nine months ended September 30, 2023, primarily attributed to organic growth and the acquisitions of the operations of Tennessee Quality Care on August 1, 2023.

Gross profit, expressed as a percentage of net service revenues, was 46.8% and 47.0% for the three months ended September 30, 2024 and 2023, respectively, and 47.3% and 46.2% for the nine months ended September 30, 2024 and 2023, respectively. For the three months ended September 30, 2024, gross profit was relatively consistent with the prior period, and for the nine months ended September 30, 2024, the increase was mainly attributed to a decrease in direct care wages, taxes and benefit costs as a percentage of net service revenues.

The hospice segment's general and administrative expenses primarily consist of administrative employee wages, taxes and benefit costs, rent, information technology and office expenses. General and administrative expenses, expressed as a percentage of net service revenues, were 24.6% and 24.9% for the three months ended September 30, 2024 and 2023, respectively, and 24.2% and 25.6% for the nine months ended September 30, 2024 and 2023, respectively. The decrease in general and administrative expenses as a percentage of net service revenues was primarily due to more efficient operations for administrative employees for the three and nine months ended September 30, 2024.

## Home Health Segment

	For the Three Months Ended September 30,						For the Nine Months Ended September 30,					
	2024		2023		Change		2024		2023		Change	
	Amount	% of Segment Net Service Revenues	Amount	% of Segment Net Service Revenues	Amount	%	Amount	% of Segment Net Service Revenues	Amount	% of Segment Net Service Revenues	Amount	%
	(Amounts in Thousands, Except Percentages)						(Amounts in Thousands, Except Percentages)					
<b>Operating Results</b>												
Net service revenues	\$ 17,045	100.0 %	\$ 15,718	100.0 %	\$ 1,327	8.4 %	\$ 52,000	100.0 %	\$ 39,659	100.0 %	\$ 12,341	31.1 %
Cost of services revenues	10,841	63.6	10,028	63.8	813	8.1	33,186	63.8	24,646	62.1	8,540	34.6
Gross profit	6,204	36.4	5,690	36.2	514	9.0	18,814	36.2	15,013	37.9	3,801	25.3
General and administrative expenses	4,338	25.5	4,131	26.3	207	5.0	13,447	25.9	9,653	24.3	3,794	39.3
Segment operating income	\$ 1,866	10.9 %	\$ 1,559	9.9 %	\$ 307	19.7 %	\$ 5,367	10.3 %	\$ 5,360	13.6 %	\$ 6.5	0.1 %
<b>Business Metrics (Actual Numbers)</b>												
Locations at period end							23		24			
New admissions * <sup>(1)</sup>	4,437		4,265		172	4.0 %	14,257		11,597		2,660	22.9 %
Recertifications * <sup>(2)</sup>	3,353		2,672		681	25.5	9,798		5,816		3,982	68.5
Total volume * <sup>(3)</sup>	7,790		6,937		853	12.3	24,055		17,413		6,642	38.1
Visits * <sup>(4)</sup>	104,730		94,637		10,093	10.7 %	322,713		240,758		81,955	34.0 %
Organic growth												
- Revenue * <sup>(5)</sup>	(1.7) %		(8.8) %				(5.4) %		(2.5) %			
- Admissions * <sup>(5)</sup>	(5.7) %		(18.9) %				(0.3) %		(13.5) %			

- (1) Represents new patients during the period.
- (2) A home health certification period is an episode of care that begins with a start of care visit and continues for 60 days. If at the end of the initial episode of care, the patient continues to require home health services, a recertification is required. This represents the number of recertifications during the period.
- (3) Total volume is total admissions and total recertifications in the period.
- (4) Represents number of services to patients in the period.
- (5) Revenue organic growth and admissions organic growth reflect the change in year-over-year revenue and admissions for the same store base. We define the same store base to include those stores open for at least 52 full weeks. These measures highlight the performance of existing stores, while excluding the impact of acquisitions, new store openings and closures.



## [Table of Contents](#)

\* Management deems these metrics to be key performance indicators. Management uses these metrics to monitor our performance, both in our existing operations and acquisitions. Many of these metrics serve as the basis of reported revenues and assessment of these provide direct correlation to the results of operations from period to period and facilitate comparison with the results of our peers. Historical trends established in these metrics can be used to evaluate current operating results, identify trends affecting our business, determine the allocation of resources and assess the quality and potential variability of our cash flows and earnings. We believe they are useful to investors in evaluating and understanding our business but should not be used solely in assessing the Company's performance. These key performance indicators should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented herein to fully evaluate and understand the business as a whole. These measures may not be comparable to similarly titled performance indicators used by other companies.

The home health segment generates net service revenues by providing home health services on a short-term, intermittent or episodic basis to individuals, generally to treat an illness or injury. Net service revenues from Medicare accounted for 70.6% and 72.1%, managed care organizations accounted for 24.7% and 21.9% and other accounted for 4.7% and 6.0% of total home health segment net service revenues for the three months ended September 30, 2024 and 2023, respectively. Net service revenues from Medicare accounted for 69.6% and 73.9%, managed care organizations accounted for 25.6% and 20.8% and other accounted for 4.8% and 5.3% of total home health segment net service revenues for the nine months ended September 30, 2024 and 2023, respectively. Home health services provided to Medicare beneficiaries are paid under the Medicare Home Health Prospective Payment System, which uses national, standardized 30-day period payment rates for periods of care. CMS uses the PDGM as the case-mix classification model to place periods of care into payment categories, classifying patients based on clinical characteristics. An outlier adjustment may be paid for periods of care in which costs exceed a specific threshold amount.

Home health net service revenues increased by \$1.3 million and \$12.3 million for the three and nine months ended September 30, 2024, respectively, compared to the three and nine months ended September 30, 2023. Total visits increased for the three months and nine months ended September 30, 2024, mainly attributed to the acquisition of Tennessee Quality Care on August 1, 2023.

Gross profit, expressed as a percentage of net service revenues, was 36.4% and 36.2% for the three months ended September 30, 2024 and 2023, respectively, and 36.2% and 37.9% for the nine months ended September 30, 2024 and 2023, respectively. For the nine months ended September 30, 2024, the decrease was primarily due to an increase in direct care wages compared to net service revenues.

The home health segment's general and administrative expenses primarily consist of administrative employee wages, taxes and benefit costs, rent, information technology and office expenses. General and administrative expenses, expressed as a percentage of net service revenues, were 25.5% and 26.3% for the three months ended September 30, 2024 and 2023, respectively, and 25.9% and 24.3% for the nine months ended September 30, 2024 and 2023, respectively. The increase in general and administrative expenses as a percentage of net service revenues was primarily due to increases in administrative employee wages, taxes and benefit costs for the nine months ended September 30, 2024.

## **Liquidity and Capital Resources**

### **Overview**

Our primary sources of liquidity are cash on hand and cash from operations and borrowings under our credit facility. At September 30, 2024 and December 31, 2023, we had cash balances of \$222.9 million and \$64.8 million, respectively. At September 30, 2024, we had a \$600.0 million revolving credit facility and a \$125.0 million incremental loan facility, which may be for term loans or an increase to the revolving loan commitments. The maturity of this credit facility, as of September 30, 2024, was July 30, 2026. It was subsequently extended to July 30, 2028.

During the nine months ended September 30, 2024, we used \$0.4 million in cash to fund the Upstate acquisition and repaid \$126.4 million under our revolving credit facility. As of September 30, 2024, we had no revolving loans outstanding on our credit facility and after giving effect to the amount drawn on our credit facility, approximately \$8.0 million of outstanding letters of credit and borrowing limits based on an advance multiple of adjusted EBITDA (as defined in the Credit Agreement), we had \$511.5 million of capacity and \$503.5 million available for borrowing under our credit facility. At December 31, 2023, we had a total of \$126.4 million revolving credit loans, with an interest rate of 7.21%, outstanding on our credit facility.

Our credit facility requires us to maintain a total net leverage ratio not exceeding 3.75:1.00. At September 30, 2024, we were in compliance with our financial covenants under the Credit Agreement. Although we believe our liquidity position remains strong, we can provide no assurance that we will remain in compliance with the covenants in our Credit Agreement, and in the future, it may prove necessary to seek an amendment with the bank lending group under our credit facility. Additionally, there can be no assurance that we will be able to raise additional funds on terms acceptable to us, if at all.

See Note 9 to the Notes to Unaudited Condensed Consolidated Financial Statements, *Long-Term Debt*, and Note 14 to the Notes to Unaudited Condensed Consolidated Financial Statements, *Subsequent Events*, for additional details of our long-term debt.

### ***Public Offering***

On June 28, 2024, the Company completed a public offering of an aggregate 1,725,000 shares of common stock, par value \$0.001 per share, including 225,000 shares of common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a public offering price of \$108.00 per share (the “Public Offering”). The Company received net proceeds of approximately \$175.6 million, after deducting underwriting discounts and estimated offering expenses of approximately \$10.7 million. The Company used approximately \$81.4 million from the net proceeds of the Public Offering for the repayment of indebtedness outstanding under its credit facility and may use any remaining net proceeds of the Public Offering for general corporate purposes, including the Company’s previously announced planned acquisition of the personal care assets of Gentiva and any future acquisitions or investments. The Public Offering resulted in an increase to additional paid in capital of approximately \$175.6 million on the Company’s Unaudited Condensed Consolidated Balance Sheet at June 30, 2024.

### ***Current Macroeconomic Conditions and COVID-19 Relief Funding***

Economic conditions in the United States continue to be challenging in various respects. For example, the United States economy continues to experience inflationary pressures, elevated interest rates and challenging labor market conditions. Any resulting economic downturn would pose a risk to states’ revenues, which in turn could affect our reimbursements and collections received for services rendered. Depending on the severity and length of any potential economic downturn as well as the extent of any federal support, states could face significant fiscal challenges and revise their revenue forecasts and adjust their budgets, and sales tax collections and income tax withholdings could be depressed.

#### *ARPA Spending Plans*

The ARPA provides for \$350 billion in relief funding for eligible state, local, territorial, and Tribal governments to mitigate the fiscal effects of the COVID-19 public health emergency. Additionally, the law provided for a 10 percentage point increase in federal matching funds for Medicaid HCBS from April 1, 2021, through March 31, 2022, provided the state satisfied certain conditions. States are permitted to use the state funds equivalent to the additional federal funds through March 31, 2025. States must use the monies attributable to this matching fund increase to supplement, not supplant, their level of state spending for the implementation of activities enhanced under the Medicaid HCBS in effect as of April 1, 2021.

HCBS spending plans for the additional matching funds vary by state, but common initiatives in which the Company is participating include those aimed at strengthening the provider workforce (e.g., efforts to recruit, retain, and train direct service providers). The Company is required to properly and fully document the use of such funds in reports to the state in which the funds originated. Funds may be subject to recoupment if not expended or if they are expended on non-approved uses.

During the three and nine months ended September 30, 2024, the Company received additional state funding provided by the ARPA in an aggregate amount of \$3.2 million and \$15.4 million, respectively. Of the total state funding received by the Company pursuant to the ARPA through September 30, 2024, the Company utilized \$2.6 million and \$7.5 million during the three and nine months ended September 30, 2024, respectively, primarily for caregivers and adding support to recruiting and retention efforts, included as a reduction of cost of service revenues in the Company’s Unaudited Condensed Consolidated Statements of Income. As of September 30, 2024, the deferred portion of ARPA funding of \$13.7 million is included within Government stimulus advances on the Company’s Unaudited Condensed Consolidated Balance Sheets.

#### *Medicare sequester*

The CARES Act and related laws temporarily lifted the Medicare sequester, which would have otherwise reduced payments to Medicare providers by 2% as required by the Budget Control Act of 2011, from May 1, 2020, through March 31, 2022. The sequestration payment adjustment was phased back in with a 1% reduction beginning April 1, 2022, and returned to 2% on July 1, 2022. These sequestration cuts have been extended through April 2032.

## [Table of Contents](#)

However, the ARPA increased the federal budget deficit in a manner that triggers an additional statutorily mandated sequestration under the PAYGO Act. As a result, an additional Medicare payment reduction of up to 4% was required to take effect in January 2022. However, Congress has delayed implementation of this payment reduction until 2025. We cannot currently determine if, or to what extent, our business, results of operations, financial condition or liquidity will ultimately be impacted by mandated sequestration triggers under the PAYGO Act, or if or when the mandated sequestration will occur. Further, we anticipate that the federal deficit will continue to place pressure on government healthcare programs, and it is possible that future deficit reduction legislation will impose additional Medicare spending reductions.

### **Cash Flows**

The following table summarizes changes in our cash flows:

	For the Nine Months Ended September 30,	
	2024	2023
	(Amounts in Thousands)	
Net cash provided by operating activities	\$ 106,016	\$ 82,198
Net cash used in investing activities	(124)	(113,934)
Net cash provided by financing activities	52,169	31,525

#### *Nine Months Ended September 30, 2024 Compared to Nine Months Ended September 30, 2023*

Cash flows from operating activities represent the inflow of cash from our payors and the outflow of cash for payroll and payroll taxes, operating expenses, interest and taxes. Net cash provided by operating activities was \$106.0 million for the nine months ended September 30, 2024, compared to net cash provided by operating activities of \$82.2 million for the same period in 2023. The increase in cash provided by operations was primarily due to the timing of receipts on accounts receivable and the timing of government stimulus funds. The changes in accounts receivable were primarily related to the growth in revenue and a decrease in days sales outstanding (“DSO”) during the nine months ended September 30, 2024 compared to 2023, as described below. The related receivables due from the Illinois Department on Aging represented 21.7% and 20.5% of the Company’s net accounts receivable at September 30, 2024 and September 30, 2023, respectively, as discussed below.

Net cash used in investing activities for the nine months ended September 30, 2024 primarily consisted of \$0.4 million of net cash used for the Upstate acquisition and \$4.4 million for property and equipment purchases, which were primarily related to our ongoing investments in our technology infrastructure, offset by \$4.6 million in proceeds received as a deposit on the sale of our New York business. Net cash used in investing activities for the nine months ended September 30, 2023 primarily consisted of \$112.2 million of net cash used for the Tennessee Quality Care acquisition. For the nine months ended September 30, 2023, property and equipment purchases, primarily related to our ongoing investments in our technology infrastructure, were \$1.7 million.

Net cash provided by financing activities for the nine months ended September 30, 2024 primarily related to a \$126.4 million payment on the revolver portion of our credit facility, offset by \$175.6 million in net proceeds received from the Public Offering, and also included cash received from the exercise of stock options of \$3.0 million. Net cash provided by financing activities for the nine months ended September 30, 2023 primarily related to borrowings of \$110.0 million on the revolver portion of our credit facility to fund, in part, the Tennessee Quality Care acquisition, partially offset by a \$78.5 million payment on the revolver portion of our credit facility.

#### **Outstanding Accounts Receivable**

Gross accounts receivable as of September 30, 2024 and December 31, 2023 were approximately \$100.0 million and \$117.8 million, respectively. Outstanding accounts receivable, net of allowance for credit losses, decreased by \$18.9 million as of September 30, 2024 as compared to December 31, 2023. Accounts receivable for the Illinois Department on Aging decreased approximately \$8.0 million during the nine months ended September 30, 2024. Our collection procedures include review of account aging and direct contact with our payors. We have historically not used collection agencies. An uncollectible amount is written off to the allowance account after reasonable collection efforts have been exhausted.

We calculate our DSO by taking the trade accounts receivable outstanding, net of allowance for credit losses for doubtful accounts, divided by the net service revenues for the last quarter, multiplied by the number of days in that quarter. Our DSOs were 32 days and 39 days at September 30, 2024 and December 31, 2023, respectively. The DSOs for our largest payor, the Illinois Department on Aging, were 33 days and 50 days at September 30, 2024 and December 31, 2023, respectively.

[Table of Contents](#)

***Off-Balance Sheet Arrangements***

As of September 30, 2024, we did not have any off-balance sheet guarantees or arrangements with unconsolidated entities.

***Critical Accounting Policies and Estimates***

There have been no material changes to our critical accounting policies and estimates previously disclosed under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Critical Accounting Policies and Estimates” set forth in Part II, Item 7 of our Annual Report on Form 10-K for the period ended December 31, 2023, filed on February 27, 2024.

***Recently Issued Accounting Pronouncements***

Refer to Note 2 to the Notes to Unaudited Condensed Consolidated Financial Statements for further discussion.

### **ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

We are exposed to market risk associated with changes in interest rates on our variable rate long-term debt. As of September 30, 2024, however, we had no outstanding borrowings on our credit facility. We do not currently have any derivative or hedging arrangements, or other known exposures, to changes in interest rates.

### **ITEM 4. CONTROLS AND PROCEDURES**

#### ***Evaluation of Disclosure Controls and Procedures***

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2024. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) means controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Based on the evaluation of our disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2024.

#### ***Changes in Internal Control Over Financial Reporting***

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the fiscal quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## PART II – OTHER INFORMATION

### Item 1. Legal Proceedings

#### *Legal Proceedings*

As disclosed in Note 11 to the Condensed Consolidated Financial Statements in Part I, Item 1—“Financial Statements (Unaudited),” which is incorporated herein by reference, from time to time, we are subject to legal and/or administrative proceedings incidental to our business. It is the opinion of management that the outcome of pending legal and/or administrative proceedings will not have a material effect on our financial position and results of operations.

### Item 1A. Risk Factors

Investing in our common stock involves a high degree of risk. You should carefully consider the risk factors discussed under the caption “Risk Factors” set forth in Part I, Item 1A, of our Annual Report on Form 10-K for the year ended December 31, 2023, filed on February 27, 2024. Except as set forth below, there have been no material changes to the risk factors previously disclosed under the caption “Risk Factors” in our Annual Report on Form 10-K. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or operating results.

#### *We may fail to complete the acquisition of Gentiva on a timely basis or at all and may not realize the benefits that are anticipated from the Gentiva Acquisition.*

We have entered into the Gentiva Purchase Agreement to acquire the personal care business of Gentiva, for a purchase price of approximately \$350.0 million, payable in full in cash at the closing, subject to customary adjustments for working capital and other items. The Gentiva Acquisition is expected to close upon the completion of regulatory approvals and subject to the satisfaction of other closing conditions.

We cannot provide any assurance that we will be able to successfully consummate the Gentiva Acquisition as provided for under the Gentiva Purchase Agreement, or, if such acquisition is completed, we cannot predict the timing of such closing. In addition, we have incurred, and will continue to incur, significant costs, expenses and fees for professional services and other transaction costs in connection with the Gentiva Acquisition, and these fees and costs are payable by us regardless of whether the Gentiva Acquisition is consummated. If we fail to consummate the Gentiva Acquisition or should the completion be significantly delayed, we could fail to realize all or a portion of the intended economic benefits of such acquisition. Any failure to complete the Gentiva Acquisition could have a negative impact on our business, financial condition and the market price of our common stock.

The benefits that are expected to result from the Gentiva Acquisition will depend, in part, on our ability to realize the growth opportunities we anticipate from the Gentiva Acquisition, which is contingent, in part, on successful integration and Gentiva performing in accordance with our expectations. Even a successful integration and meeting performance expectations may not result in the realization of the full benefits we currently expect, nor can we give assurances that these benefits will be achieved when expected or at all. Moreover, we expect to incur expenses in connection with the integration of Gentiva, and as such, the benefits may be offset by costs incurred or delays in integrating the businesses. Further, our due diligence review of Gentiva may not have successfully identified all potential issues. In addition, the integration of Gentiva may result in material unanticipated problems, expenses, liabilities, regulatory risks, and diversion of management’s attention.

The pendency of the Gentiva Acquisition could cause disruptions and create uncertainty surrounding our business and affect our relationships with our customers and employees. We have diverted, and will continue to divert, significant management resources to complete the Gentiva Acquisition, which could have a negative impact on our ability to manage existing operations or pursue alternative strategic transactions, which could adversely affect our business, financial condition and results of operations. Until the completion of the Gentiva Acquisition, holders of shares of our common stock will be exposed to the risks faced by our existing business without any of the potential benefits from the Gentiva Acquisition. As a result of investor perceptions about the terms, conditions, risks or benefits of the Gentiva Acquisition, the market price of shares of our common stock may decline.

### Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

### Item 3. Defaults Upon Senior Securities

None.

[Table of Contents](#)

**Item 4. Mine Safety Disclosures**

None.

**Item 5. Other Information**

During the quarter ending September 30, 2024, each of the following directors and Section 16 officers adopted a Rule 10b5-1 Trading Arrangement (as defined in Item 408(a) of Regulation S-K) to sell common shares:

Name	Title	Adoption Date	Expiration Date <sup>(1)</sup>	Shares Vesting and Subject to Sell-To-Cover <sup>(2)</sup>	Other Shares Being Sold (Subject to Certain Conditions)
R. Dirk Allison	Chief Executive Officer and Chairman of the Board	August 26, 2024	August 26, 2025	n/a	87,500 <sup>(3)</sup>

<sup>(1)</sup> Each plan will expire on the date represented in the table or upon the earlier completion of all transactions contemplated by the arrangement.

<sup>(2)</sup> This column indicates the total number of shares vesting in connection with equity awards, not the number of shares to be sold. The actual number of shares to be sold will be a smaller number based on whatever is required to satisfy payment of applicable withholding taxes under sell-to-cover arrangements.

<sup>(3)</sup> Mr. Allison became CEO of the Company in early 2016 and, in connection with that appointment, received a grant of options with respect to 150,000 shares on January 21, 2016, of which 87,500 remain outstanding and unexercised. Those options have a ten-year term and are thus forfeited if not exercised by early 2026. Mr. Allison has established this plan in order to effectuate an orderly process for exercising and selling before the date of forfeiture.

Each trading arrangement noted above is intended to satisfy the affirmative defense in Rule 10b5-1(c). No other director or Section 16 officer adopted or terminated any Rule 10b5-1 trading arrangements or non-Rule 10b5-1 trading arrangements, as such terms are defined in Item 408(a) of Regulation S-K, during the quarter ending September 30, 2024.

[Table of Contents](#)

## Item 6. Exhibits

## EXHIBIT INDEX

Exhibit Number	Description of Document	Incorporated by Reference			Exhibit Number
		Form	File No.	Date Filing	
<a href="#">3.1</a>	<a href="#">Amended and Restated Certificate of Incorporation of the Company dated as of October 27, 2009.</a>	10-Q	001-34504	11/20/2009	3.1
<a href="#">3.2</a>	<a href="#">Amended and Restated Bylaws of the Company, as amended by the First Amendment to the Amended and Restated Bylaws.</a>	10-Q	001-34504	5/9/2013	3.2
<a href="#">4.1</a>	<a href="#">Form of Common Stock Certificate.</a>	S-1	333-160634	10/2/2009	4.1
<a href="#">31.1</a>	<a href="#">Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>				
<a href="#">31.2</a>	<a href="#">Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>				
<a href="#">32.1</a>	<a href="#">Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>				
<a href="#">32.2</a>	<a href="#">Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>				
101.INS	Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).				
101.SCH	Inline XBRL Taxonomy Extension Schema Document.				
101.CAL	Inline XBRL Taxonomy Calculation Linkbase Document.				
101.LAB	Inline XBRL Taxonomy Label Linkbase Document.				
101.PRE	Inline XBRL Presentation Linkbase Document.				
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document.				
104	Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101).				



**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

***ADDUS HOMECARE CORPORATION***

Date: November 5, 2024

By: \_\_\_\_\_ /s/ R. DIRK ALLISON

**R. Dirk Allison  
Chairman and Chief Executive Officer  
(As Principal Executive Officer)**

Date: November 5, 2024

By: \_\_\_\_\_ /s/ BRIAN POFF

**Brian Poff  
Chief Financial Officer  
(As Principal Financial Officer)**

**CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER  
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, R. Dirk Allison, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Addus HomeCare Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 5, 2024

By: /s/ R. Dirk Allison

\_\_\_\_\_  
R. Dirk Allison  
Chairman and Chief Executive Officer

**CERTIFICATIONS OF CHIEF FINANCIAL OFFICER  
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Brian Poff, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Addus HomeCare Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 5, 2024

By: /s/ Brian Poff

Brian Poff

Chief Financial Officer

---

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER  
PURSUANT TO 18 U.S.C. SECTION 1350  
(AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)**

In connection with the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024 of Addus HomeCare Corporation (the "Company") as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, R. Dirk Allison, Chairman and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 5, 2024

By: /s/ R. Dirk Allison

R. Dirk Allison  
Chairman and Chief Executive Officer

---

**CERTIFICATION OF CHIEF FINANCIAL OFFICER  
PURSUANT TO 18 U.S.C. SECTION 1350  
(AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)**

In connection with the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024 of Addus HomeCare Corporation (the "Company") as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Brian Poff, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 5, 2024

By: /s/ Brian Poff

Brian Poff  
Chief Financial Officer

---

